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INTERNALIZING SYMPTOMS, MEDICATION ADHERENCE, AND PERCEIVED SOCIAL  
 




This study examined the role of perceived social support (PSS) for individuals with 
inflammatory bowel disease (IBD).  Patients were recruited for this study from online forums 
consisting of Facebook support groups, Twitter followers, and email.  This study investigated 
sociodemographic and disease-related predictors of disease severity for individuals with IBD, as 
well as whether or not perceived social support moderates the relationship between disease 
severity, internalizing symptoms, quality of life, and medication adherence.  A sample size of 
155 individuals self-reporting with inflammatory bowel disease (ulcerative colitis or Crohn's 
disease) completed questionnaires related to disease severity, disease type, disease duration, 
quality of life, depression, anxiety, stress, perceived social support, and medication adherence.  
The study findings suggest that anxiety and stress are potential predictors of scores on disease 
severity for this population.  Results also suggests that perceived social support is likely to have 
(or had in this sample) a significant, moderating relationship between disease severity and 
anxiety, disease severity and stress, and disease severity and the full depression, anxiety and 
stress scale (DASS).  Anxiety was also found to moderate the relationship between disease 
severity and adjusted quality of life (QoL) scale.  PSS did not moderate the relationship between 
disease severity and the abbreviated medication adherence rating scale (MARS) generated by 
principle component analysis.  It is important to note that future research should include a more 





psychological impact associated with this disease provides continued evidence for the need 
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Inflammatory bowel disease (IBD) 
Gastrointestinal disorders have been significantly underrepresented in psychological 
literature, particularly inflammatory bowel disease (IBD).  As medical practitioners discover 
more factors contributing to the etiology and physiology of gastrointestinal disorders, research 
concerning the psychosocial effects of the illness remains well behind in comparison (Graff, 
Walker, & Bernstein, 2009; Wen & Fiocchi, 2004).  In order to understand why the psychosocial 
effects of IBD are so emotionally taxing, it is essential to first understand the biology and 
physical impact of the disease (Matthews, Gallo & Taylor, 2010).  Exploring the biological 
mechanisms involved in IBD disease etiology serves to elucidate the complexity of the illness. 
IBD is a chronic, autoimmune disease of the gastrointestinal tract affecting approximately 
1.6 million Americans (Kilham, Lerner, & Griffiths, 2014).  The average age of onset for IBD is 
between 15-25 years old (Saunders, 2014). Rates of IBD are the most prevalent amongst Jewish 
individuals than any other ethnic group, and are much higher in European countries (Molodecky 
et al., 2012).  It is a disease in which the chemistry of the bowel is significantly altered by 
inflammation, bleeding ulcers, and mucosal secretions (Podolsky, 1991).  As the chemistry of the 
bowel is affected, so too, is its ability to function normally.  This physiological alteration results 
in increased bowel urgency, excessive diarrhea, undigested food, fatty deposits in the stool, loss 
of blood, persistent fatigue, extreme weight loss and anemia (Podolsky, 1991; Opheim, 
Fagermoen, Bernklev, Jelsness-Jorgensen, & Moum, 2014).  An individual experiencing these 
symptoms typically receives a formal diagnosis from a gastroenterologist, via colonoscopy, to 




 are Crohn’s disease (CD) and ulcerative colitis (UC) (Shorter, Huizenga, Spencer, & Guy, 
1972).  These two diseases are grouped together because of similarities in symptom presentation.  
Despite their similarities, understanding the differences between the UC and CD is vital for 
research and treatment purposes. Refer to Table 1.  
Table 1. Disease Differences between UC and CD 
 
Disease Ulcerative Colitis Crohn’s Disease 
Location Colonic mucosa only (large intestine 
and colon) 
Transmural mucosa, which includes 
entire gastrointestinal tract from 
mouth to anus 
Inflammation Inflammation occurs in a continuous 
pattern in affected areas 
Inflammation may be in patches and 
intermittent 
Pain Pain is usually in the lower left side 
of the abdomen 
Pain is usually in the lower right side 
of the abdomen 
Appearance Colon wall is thinner and shows 
continuous inflammation, ulcers do 
not extend beyond inner lining  
Colon wall is thicker and may have a 
rocky appearance, ulcers are deep 
and may extend into all layers of the 
bowel wall 
Bleeding Bleeding from rectum during bowel 
movements is not common 
Bleeding from rectum during bowel 
movements is very common 
Complications Fistulas, fissures, and strictures 
common 
Not common in UC; severe anemia 
common 
Treatment 5-Aminosalicylates (5-ASAs) and 
steroids are common, recent success 
with anti-TNF-α medications 
Steroids are common, not as many 5 
ASAs are used, first to show success 
with anti-TNF-α medications 
Surgery Total colectomy (removal of large 
intestine and colon) is considered a 
‘cure’-patient can then have internal 
or external pouching system 
Bowel resections to remove 
significant diseased portions are 
possible, but colectomy is not a 
‘cure’ because it is pervasive in the 
entire gastrointestinal tract and could 
result in more surgeries 
 
The difference in presentation between UC and CD can result in vastly different 
treatment plans and prognoses for patients (Schurman, Cushing, Carpenter, & Christenson, 
2011).  Patients with UC have the option of a colectomy, which is a surgery to remove the entire 
colon.  For patients with UC, surgery is considered the only option that could potentially rid the 




(Moris, 2014).  CD, in comparison, involves transmural mucosa that can affect the entire 
gastrointestinal tract, which extends from the mouth to the anus.  Although patients with UC can 
receive a curative form of surgery that removes the entire diseased portion of the large intestine.  
Patients with CD can only manage their disease with bowel resections and medication (Moris, 
2014).   
Individuals needing surgical intervention with UC typically receive either an internal or 
external pouching system.  The most common surgery for UC is a procedure that results in an 
ileal pouch anal anastomosis (IPAA) (Hahnloser et al., 2007).  This is a surgery that is completed 
by diverting the lower portion of the small intestine (the ileum) through a small opening in the 
abdominal wall, called a stoma (Hallbook, Hass, Wanstrom, & Sjodahl, 1997).  A pouching 
system is then attached to the outside of the skin and around the stoma to collect waste from the 
opening.  An ileostomy can be permanent, in which case, the external pouching system would 
remain indefinitely.  An individual who has had this procedure, often colloquially referred to as 
‘j-pouch’ surgery, has the option of a reversal surgery.  The j-pouch is created from the lower 
portion of the ileum that is pulled down and sewn together in the shape of a ‘j’ (Martin et al., 
2011).  In a reversal surgery, the mucosa that has created the stoma is disconnected from the 
outside of the skin and reconnected internally (Ba’ath et al., 2007).  The internal pouching 
system made from the lower portion of the ileum (the j-pouch) then acts as the waste removal 
system for the body (Martin et al., 2011).  While this surgery helps eliminate life-threatening 
symptoms, it is associated with the development of other complications, including; incontinence, 
pouchitis (inflammation and bleeding in the j-pouch), pelvic sepsis, and cuffitis (Hallbook et al., 




These surgical processes involve substantial health risks, and are associated with high 
levels of pain and discomfort.  Patients can potentially experience negative, psychological and 
emotional effects as they transition through this process (Bekkers et al., 1995).  The emotional 
and psychological changes that occur when adapting to their illness can then result in other 
personal and social struggles for individuals with the disease.  Many patients lose their jobs due 
to prolonged sick leave, undergo financial strain due to medical bills, and lose friendships and 
relationships as a result of the debilitating, often isolating symptoms (Taft, Keefer, Artz, Bratten, 
& Jones, 2011).  Levels of perceived stigma increase these feeling of isolation and exclusion 
(Saunders, 2014; Joachim & Acorn, 2000; Looper & Kirmayer, 2004). It is not uncommon for 
individuals with IBD to feel an overall loss of identity because the illness has usurped a great 
deal of the personal and professional agency they once possessed (Taft et al., 2011; Joachim, 
2002).    
The severity of symptoms in CD can potentially be more traumatic and life-threatening 
than that of the symptoms of UC (Cámara, Gander, Begré & von Känel, 2011).  In CD a 
thickness in the intestinal wall occurs, resulting in a rocky, callous presentation (Farrell & 
Savage, 2012).  Bowel obstructions can occur when the intestinal wall has become too thick to 
allow food or other substances to pass through; bowel obstructions are more common for 
individuals with CD than individuals with UC (Yaffe & Korelitz, 1983).  The small intestine is 
responsible for the body’s nutrient absorption, and as such, individuals with CD are at greater 
risk of malabsorption complications and food-induced bowel obstructions (Massironi et al., 
2013).  CD can surface in any part of the gastrointestinal (GI) tract, and often does so without 
any apparent pattern, unlike the gradual, predictable spread of UC.  The removal of severely 




 1991).  Individuals that have had a portion of their small intestine removed may develop a 
condition referred to as ‘short bowel syndrome’ in which the remaining intestine is too short to 
allow for nutrient absorption (Kaufman, Mazariegos, & Reyes, 2006).  This syndrome often 
leaves patients completely dependent on total parenternal nutrition (TPN), which is an 
intravenous method of receiving nutrients (Rajendran & Kumar, 2010).  Unlike UC, where a 
temporary ileostomy is an option, individuals with CD often need a permanent external pouching 
system, or which can be either an ileostomy or a colostomy, as the disease progresses and their 
nutrient absorption rates decline (Cosnes et al., 2005).  A colostomy is a rerouting of the large 
intestine that connects the colon the abdominal wall.  When individuals with UC receive their 
ileostomy, this reduces their dependence on invasive medications with significant side effects, 
whereas individuals with CD will still require these medications as part of lifelong, disease 
management (Kaufman, et al., 2006).       
Stoma creations can cause severe physical, emotional and social challenges for 
individuals, and can significantly reduce QoL (Ross et al., 2007).  Those living with a permanent 
colostomy are also at risk for experiencing a higher degree of struggle with the physical aspect of 
their condition and the resultant psychosocial adjustment (Follick, Smith, & Turk, 1984).  The 
visual impact of having an external, waste system can be traumatic for some, who now view their 
bodies as tainted, and unattractive (Muller, Prosser, Bampton, Mountfield, & Andrews, 2009).  
The presence of a colostomy intensifies the stigma associated with IBD, and can cause further 
isolation (Taft et al., 2011).         
Pathogenesis  
Despite extensive research in the field, there is still no known etiology for the disease, but 




2012).  However, a compilation of animal studies, research in human genetics and a series of 
randomized clinical trials have generated new information pertaining to factors involved in the 
pathogenesis of IBD (Sartor, 2006).  Specific genetic factors which contribute to the 
development of IBD have been identified with the advancement in research techniques (Gordon, 
Moller, Andersen, & Harbord, 2015; Basso et al., 2014). 
 Recent studies have illustrated that having first-degree relatives with CD and UC is a 
significant predicting factor in the development of IBD (Moller et al., 2015).  Twin studies have 
revealed a high concordance rate in monozygotic (MZ) (identical) twins for each subsequent 
disease. MZ twins presenting with CD are estimated to have a 50% rate of concordance and 
those presenting with UC are estimated to have approximately 19% concordance, suggesting a 
strong genetic link in the passing and manifestation of IBD (Halfvarson, Bodin, Tysk, Lindberg, 
& Järnerot, 2003; Brant, 2011; Sheehan, Moran, Shanahan, 2015; Orholm et al., 1991).  Some 
researchers report lower concordance rates between MZ twins and dizygotic (DZ) twins 
suggesting that there is a 30.3% concordance rate between MZ twins with CD, and a 15.4% 
concordance rate for MZ twins with UC (Cho & Brant, 2011).  Cho and colleagues (2011) 
suggest that the concordance rate is 3.6% for DZ twins with CD, and 3.9% for DZ twins with 
UC.   
Ongoing research in IBD twin studies is now looking beyond concordance rates and is 
examining the role of gut microbiota associated with the disease (Cosnes, Gower-Rousseau, 
Seksik, & Cortot, 2011).  The basis for studying the microbiota in twins stems from discovering 
a recent trend of increased occurrence of IBD in societies becoming more industrialized (Cosnes, 
et al., 2011).  Researchers want to examine whether or not there is a correlation between this 




colleagues (2011) assert that the trend in transitioning societies to more ‘Westernized 
environments’ appears to show an increase in UC first, followed by an increase in CD.  Changes 
in environmental stressors, changes in diet and socioeconomic status alter what the gut is 
exposed to, which impacts the balance of microbiota (Cosnes et al., 2011).        
Perhaps most promising in the realm of genetic hypotheses surrounding development of 
IBD is the usage of genome wide studies (GWAs) for progressive research in the genetic and 
microbiome areas.  Approximately 160 loci have been identified in the pathology of IBD, 
suggesting an array of genes associated with its etiology (Knights, Lassen, Xavier, 2013).  These 
loci are associated with the etiopathogenesis of IBD, and some have been identified as specific 
for CD, some specific for UC, and some encompass both diseases (Hold et al., 2014; Jostins et 
al., 2012).  One of the original genes in these discoveries was the caspase recruitment domain 
family member 15 (CARD15), which is observed in 25-35% of CD patients and is hypothesized 
to double the likelihood of developing CD with a heterozygous allele combination, and to 
increase the likelihood by 20-fold with a homozygous allele combination (Maloy & Powrie, 
2011).  CARD15 is also referred to as nucleotide-binding oligomerization domain containing 2 
(NOD2).  A mutation in this gene can result in amino acid substitutions that prevent recognition 
of pathogenic bacteria, potentially resulting in a dysbiotic intestinal biota as a result (Sartor, 
2006).   
As genetic research surrounding the pathogenesis of IBD has increased in the last decade, 
so, too, has research examining microbial involvement in the potential etiology of the disease 
(Hold et al., 2014).  This research considers the continuous, abnormal inflammatory response 
between communal microbes in a host (host-mutualism).  The said host of these microbes has 




associated with the disease (Khor, Gardet, & Xavier, 2011).  This idea of dysbiosis, or imbalance 
of healthy and harmful gut microbiomes, has become integral to the understanding of IBD.  
However, researchers are still mystified as to whether this change of normal gut microbiomes as 
a result of host-microbial mutualism is a result of, or a contributing factor to, the development of 
IBD (Khor et al., 2011).  Researchers do not know which existed first, the microbial imbalance 
impacting the disease, or the disease leading to microbial imbalance (Knowles & Mikocka-
Walus, 2015).  Knowles and researchers (2015) also do not know if there are shifts in the 
microbiota during the course of the disease, and how this might impact the prognosis and 
treatment symptoms.  Hold et al. (2014) posits that the shift of looking for external 
environmental triggers, to those within our own bodies, or an ‘in-vironment’ triggers has shed 
further light on the connection of gut bacteria to immune system function.    
The specific genes that impact the pathogenesis of IBD are all associated with immune 
system responses, the mucosal functioning of the intestines, and in elimination of deleterious 
bacterial (Sartor, 2006).  The immune system response of greatest concern that has been 
identified in IBD involves an over-activation of T-cells.  There is an imbalance between Th-1 
cells and Th-2 cells for individuals with IBD (Knowles et al., 2015; Lo, Arsenescu & Friedman, 
2013).  Medications targeting the deactivation of the tumor necrosis factor-alpha (TNF-α), a pro-
inflammatory protein secreted by macrophages and other immune cells, have resulted in 
symptom reduction for individuals with both CD and UC (D’Haens & Daperno, 2006).  Due to 
the efficacy of the antibodies in regulating the immune response, these medications, such as 
Remicade (Infliximab), Imuran (Azathioprine) and Humira (Adalimumab), are utilized in the 





Similar to genetic and immunological factors, environmental factors are hypothesized to 
alter mucosal barrier function, immune system responses, and the bacterial microenvironment of 
the intestines (Sartor, 2006).  The fact that some individuals develop IBD in childhood and 
others in adulthood, seems to suggest that there are environmental factors associated in the 
manifestation of the disease in individuals born with a genetic predisposition (Graham & Xavier, 
2013).  Multiple environmental factors (outside of the emphasis on societies becoming more 
industrialized correlating with an increased prevalence of IBD) are suggested as triggers for IBD, 
such as smoking, diet, antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDS), infections 
and stress (Loftus Jr., 2004, Loftus Jr, Shivashankar, Tremaine, & Zinmeister, 2014).  Each of 
these factors is said to impact susceptibility to inflammation, a symptom central to the 
classification of IBD.  The recognition of genetic, immunological, and environmental influences 
as contributing factors to the development and exacerbation of IBD, only further illustrates the 
complexity of the disease (Halfvarson et al., 2003).           
As there is no known certain etiology for IBD, it is not surprising that there is also no 
accepted, universal medical treatment that targets both forms of the disease, or one that treats all 
symptoms.  Medical professionals work with their patients to try and find the most effective 
treatment for their illness, which can sometimes result in a trial-and-error approach (Červený et 
al., 2007).  This difference in patient response to varying treatments in IBD can potentially 
expose individuals to harmful medications, sometimes even resulting in enrollment of 
experimental drug studies where long-term side effects are unknown (Červený et al., 2007).  
Symptom relief and control are often the foci of most IBD medical interventions, but there is no 
definitive explanation as to why certain individuals respond positively to steroids and immuno-




 of the disease is unique for each individual, which also makes it difficult for researchers and 
medical professionals to predict which patient’s symptoms will return if they have gone into 
remission at one point in time.   
The symptoms of IBD are considered relapsing-remitting and are often unpredictable in 
their onset and severity.  As such, they create a pervasive set of personal and social stressors 
(Griffiths, 2004).  For instance, it often becomes difficult for patients with IBD to attend social 
events due to the unpredictability of the disease symptoms, and the need to be near restroom 
facilities at all times.  Individuals with IBD may, therefore, begin isolating themselves in their 
homes and withdrawing from their social networks (Nicholas et al., 2007).      
Factors Influencing Medication Adherence in IBD 
Given that IBD has been deemed an idiopathic, chronic illness that has no cure, an 
adherence to a specific treatment regimen is essential for symptom management (Kane, Huo, 
Aikens, & Hanauer, 2003).  Individuals with IBD may then attempt to control symptoms by 
using a vast array of powerful medications and invasive treatments in order to regain a 
semblance of control over their body’s functionality and retain social interactions (Červený et al., 
2007).  These treatments are also associated with a separate host of debilitating side effects in 
addition to the existing IBD symptoms, potentially deterring individuals from medication 
adherence altogether (Kane et al., 2003; Birnie, McLeod, & Watkinson, 1981; Brawley & Culos-
Reed, 2000; DiMatteo, Lepper, & Croghan, 2000; DiMatteo ).  Medication adherence is most 
commonly defined as the ratio between the medications prescribed by a medical practitioner to 





According to Schurman and colleagues (2009), individuals who do not adhere to a 
treatment plan do so for either ‘volitional’ and/or ‘non-volitional’ reasons.  Non-volitional 
nonadherence is generally categorized as forgetting to take medication, misplacing medication, 
not being able to obtain medication for financial reasons, or not fully understanding the 
guidelines for which to take medication (Schurman et al., 2009).  Volitional, or intentional, 
nonadherence is a purposeful choice to alter the treatment plan, often based on the perceived 
physical, social, or emotional health of the patient themselves (Schurman et al., 2009).  IBD has 
been identified as an illness where individuals struggle with adherence to their medical treatment 
plans, despite the need for long-term, medical care (Ediger et al., 2007; Lopez‐Sanroman & 
Bermejo, 2006).  It is estimated that between 16-66% of individuals with IBD adhere to 
treatment plans, illustrating a high degree of variance in medication adherence between patients 
(Schurman et al., 2009; Hommel, Davis, & Baldassano, 2008).  Further research needs to 
examine the factors contributing to such large variance in medication adherence.   
Treatment regimens for IBD are usually tailored to each individual patient by a medical 
professional, and targets their particular symptoms and needs (Ediger et al., 2007).  These plans 
and can vary drastically in frequency of need, dosage, or delivery method for individuals with 
IBD (Schurman et al., 2009).  Treatment plans can include oral medications, enteral medications, 
injections, infusion-based medications, supplements for malnutrition, and dietary restrictions 
(O'Sullivan & O'Morain, 2006; Greenley et al., 2015).  Most IBD, anti-inflammatory 
medications are consumed on a daily basis (or multiple times a day), and are administered orally 
or rectally.  Alternatively, intravenous immunosuppressants (Humira, Imuran, Remicade) are 
delivered via infusions (lasting approximately 3-5 hours at an infusion site) that occur 




exist for patients in both accessibility and practicality, potentially increasing nonadherence.  
These barriers exist in addition to the often serious physical or emotional side effects that can 
emerge as a result of these medications (Selinger et al., 2013).  Painful, physical side effects of 
IBD medications include weight gain, pancreatitis, immunological suppression, increased risk of 
cancer, and rashes or skin irritation, which may act as deterrents to remain on treatment plans 
(Kane, Huo, Aikens, & Hanauer, 2003; Hommel et al., 2008).  Individuals have also reported 
intentionally altering their treatment plan because they believed they could work towards 
improved physical, social or emotional outcomes with a different approach (Schurman et al., 
2009; Mikocka-Walus, Andrews, von Känel & Moser, 2013).   
Researchers hypothesize that there may be a multitude of factors, or barriers, contributing 
to medication adherence in the IBD population (Nahon et al., 2011; Lindberg, Ebbeskog, Karlen, 
Oxelmark, 2013).  Additionally, research has shown that it is difficult to accurately study 
medication adherence within the IBD population due to a current lack of reliable and valid 
measures of adherence (Schurman et al., 2009).  Repeated studies assessing medical adherence in 
patients of chronic illnesses have illustrated the difficulty of studying this behavior in a reliable 
way (Ediger et al., 2007).  In past research, the most common methods of studying adherence 
have included self-report, pill count, or biological testing (including blood draws and urinalyses) 
(Nahon et al., 2011).  Some studies have examined patients in remission stages of the illness, and 
researchers assert that rates of relapse are higher in patients not adhering to appropriate medical 
treatment than patients who are following their prescribed plan (Kane et al., 2003). Lopez-
Sanroman and Bermejo (2006), suggest that, outside of measurement issues, there are four main 
factors that influence medication adherence in individuals with IBD: illness, treatment type (as 




between the patient and the doctor.  Patient illness perceptions and individual characteristics, can 
greatly impact decisions to seek medical care, as well as the degree to which patients adhere to 
medical treatment plans (Rochelle & Fidler, 2012).  Males have reported higher rates of 
nonadherence to medication plans within this population, as well as individuals with higher 
numbers of prescribed medications, individuals that are younger, individuals with higher rates of 
disease severity, and individuals experiencing psychiatric comorbidity (Ediger et al., 2007).  
Higher psychiatric comorbidity associated with increased rates of medication nonadherence 
suggests that the degree of internalizing symptoms experienced by IBD patients might also 
contribute to medication adherence (Selinger et al., 2013).  It is more difficult to adhere to 
treatment plans when anxiety and depression are high (Grenard et al., 2011; DiMatteo, 2004).  
DiMatteo, Lepper, & Croghan (2000) conducted a meta-analyses investigating the link between 
anxiety and depression and their relationship to treatment nonadherence.  The likelihood of 
nonadherence to treatment plans is estimated to triple in depressed individuals (DiMatteo, 
Lepper, & Croghan, 2000).  Depressed individuals might experience negative attitudes towards 
the efficacy of medication and are less optimistic that it could ease their symptoms (Kane, 
Khatibi, & Reddy, 2008).  Because belief in the efficacy of the treatment is central to medication 
adherence, it is not surprising that this depression-related hopelessness acts as a deterrent 
(DiMatteo, Lepper, & Croghan, 2000).  
Patient-physician relationships are an important component in medication adherence 
(Kane et al., 2008).  Patients have the best outcome with medication adherence when they 
collaborate with their doctors about the treatment plan (Kane et al., 2008).  This relationship can 
be categorized as a form of social support, and discord within the patient-physician relationship 




social support, medical professionals might also influence attitudes towards treatment plans for 
patients (Sewitch et al., 2003).  If individuals have a better rapport with their doctors and nurses, 
this might also impact their beliefs about the efficacy of their medications and how they take 
them (Ghosh, 2008).    
Patient characteristics impacting medication adherence include the degree to which 
patients perceive their levels of social support (Haapamäki, Turunen, Roine, Färkkilä & Arkkila, 
2009).  Patients may adhere to treatment regimens more if they have social support, as they may 
have more help in adjusting to adverse reactions or changes in their disease severity (Camara et 
al., 2011).  Having social support may increase patient self-efficacy and the belief that they 
possess the ability to manage their illness Bonsaksen, Lerdal, & Fagermoen, 2012).  In having 
other individuals check-in with, and hold one accountable, an individual might be more likely to 
continue taking their medications regularly (Camara et al., 2011).  There is also a sense of 
solidarity and unity in experiencing an illness with others who understand the difficulties, which 
can provide hope and strength for a patient (Sewitch et al., 2003).  A patient who has more hope 
that their condition will improve is also a patient more likely to continue treatment (Horne & 
Weinman, 1999).    
A lack of medication adherence not only increases health risks for individual patients, but 
it can become a financial burden on society as well (Horne et al., 1999).  These patients tend to 
have more hospitalizations, an increased number of urgent care visits, and higher treatment costs 
(Kane et al., 2008).  According to Horne and colleagues (1999), in addition to the direct financial 
loss accompanied with medical costs, a lack of treatment adherence contributes to a loss of 
productivity and increased absenteeism at places of work.  Higgins and colleagues (2009) 




healthcare costs (via disease relapse and other complications) than adherent patients.  In studying 
factors that encourage medication adherence, the resulting individual and societal costs can 
potentially be reduced. 
Although most widely used, self-report measures of medication compliance tend to show 
inflated measures of compliance most likely resulting from a ‘faking-good’ attitude (Morisky, 
Ang, Krousel‐Wood & Ward, 2008).  Kane et al. (2012) suggests that there is no acceptable, 
self-report medication adherence scale that captures the rates of medication adherence in the IBD 
population.  It is suggested that a disease-specific medication adherence scale be generated to 
fully comprehend the effect of the unique barriers to medication adherence for individuals with 
IBD (Kane at al., 2012).  Due to the consistency in reported high rates of nonadherence within 
the IBD population, it is vital to continue to uncover which factors might be most predictive in 
improving these rates.  Our study used a general, self-report measure of medication adherence 
and might have impacted the reported levels of adherence that were collected.  
Nutrition and IBD  
Environmental factors, including changes in dietary preparation and intake, have 
significantly contributed to the rising incidence of IBD throughout the world (Skrautvol & Na 
Den, 2011).  Diet and food preparation in more developed nations are said to have contributed to 
a negative shift in the microbiome of individuals in these populations (Skrautvol et al., 2011).  
This phenomenon, referred to as the hygiene hypothesis, suggests that a microbiome that has 
been insufficiently colonized by healthy bacteria, leaves individuals much more susceptible to 
the development of autoimmune disorders, such as IBD (Voreades, Kozil, & Weir, 2014).  
Various environmental factors can alter an individual’s intestinal microbiota, such as diet, 




is linked to the development of IBD, which suggests that the composition of an individual’s 
microbiome is also connected to the immune system (Ryu et al., 2008).  As a result of this 
connection, individuals with autoimmune disorders often attempt to alter the bacteria in their 
microbiomes, as the shift in active, intestinal bacteria could possibly improve the function of 
their immune systems.  When comparing the possible environmental factors that could impact an 
individual’s microbiome, research suggests that the commitment to a long-term diet has the most 
influence in building and changing the intestinal make-up (Ryu et al., 2008).  More empirical 
evidence has emerged regarding the importance of diet in both the potential prevention of IBD, 
as well as in the management of the illness after diagnosis (Olendzki et al., 2014).   
Malnutrition is a common complication for individuals with IBD.  IBD often prevents 
patients from fully digesting specific foods, also preventing the full absorption of nutrients.  
However, researchers have yet to study a diet that works across the entire IBD population 
(Vidarsdottir, Johannsdottir, Thorsdottir, Bjornsson, & Ramel, 2016).  Some patients have 
reported symptom reduction after eating certain foods, and others have said that those very same 
foods made their symptoms a great deal worse (Vidarsdottir et al., 2016).  Due to the fact that no 
specific diet plan has been effective for this population as a whole, it is suggested that each 
patient formulate their own plan based on their individual disease experience (Vidarsdottir et al., 
2016).  Patients often begin avoiding certain foods altogether based on what helps manage their 
symptoms, however, avoiding nutrient dense foods could result in significant vitamin and 
nutrient deficiencies Vidarsdottir et al., 2016).  Researchers suggest that individuals in the IBD 
population most commonly report responding negatively to, are dairy products, processed meats, 




that raw fruits and vegetables commonly exacerbate patient symptoms, presents particular 
concern in regards to potential vitamin deficiency (Vidarsdottir et al., 2016).   
As a result of these nutritional deficits, researchers have also begun to study the role of 
probiotics and prebiotics in helping restore balance in a diseased microbiome, such as those 
affected by inflammatory bowel disease (Gentschew & Ferguson, 2012).  Although prebiotic and 
probiotic use cannot prevent the occurrence of IBD, some research suggests that it can help 
increase the rates of remission in patients with IBD (Gentschew et al., 2012).  Furthermore, 
patients can consume such probiotic bacteria in numerous states, including capsule form (Penner 
& Fedorak, 2005).  Research has illustrated increased rates of disease remission in IBD patients 
taking high doses of VSL #3, a potent prebiotic.  While research concerning the nutritional 
deficits of individuals with IBD is gaining attention, it is clear that a wide gap in this literature 
currently exists (Tinsley et al, 2016).  Tinsley and colleagues (2016) suggest that significantly 
more research is needed to determine the ways in which we can increase nutrient consumption, 
and absorption, within this patient population.     
Disease Severity and Quality of Life 
Chronic illness literature has produced significant evidence that coping with a long-term 
disease can result in a reduced quality of life (QoL) for individual sufferers (Lim, Jin, & Ng, 
2012).  QoL is generally defined as a “person’s interpretation of their position in life in relation 
to the value systems in which they inhabit, their cultural background, and how this perception 
also incorporates their personal goals, standards, expectations, and concerns (Apaz et al., 2009).”  
Irvine (2004), described quality of life for individuals suffering from a chronic illness as the 
extent of the disease’s impact on a patients function, behavior and performance as well as their 




assessed using self-report measures (Pallis, Vlachonikolis, & Mouzas, 2002).  There is debate, 
however, as to the extent of the relationship between QoL and disease activity, or severity 
(Guthrie et al., 2002).  Some research suggests that the greater the disease activity in patients 
with IBD, the more reduced their QoL is reported to be.  Rochelle and colleagues (2013) suggest 
that patients who believed their active symptoms would only last a short time had higher rates of 
QoL than patients who believed their IBD would have long-lasting, serious consequences for 
their lives.  In short, individuals who believed their suffering had an end point, were able to 
enjoy higher levels of QoL (Rochelle et al., 2013).  Individuals with this disease often waver 
between hope that their disease will remain manageable, and fear that it will debilitate them 
beyond functionality (Lynch & Spence, 2008).  This incessant uncertainty and experience of 
emotional extremes can significantly worsen QoL for patients with IBD (Lynch & Spence, 
2008).   
QoL measurements are common in research associated with chronic illness, and, in 
particular, research examining IBD adjustment (Rochelle et al., 2013; Lynch & Spence, 2008; 
Kalafateli et al., 2013).  Studies have illustrated mixed results regarding whether or not duration 
of disease (measured in years after diagnosis) affects QoL for patients (Huppertz-Hauss et al., 
1993; Jäghult, Saboonchi, Johansson, Wredling,& Kapraali, 2011).  Some research suggests that 
the newer the diagnosis, the lower the QoL reported by individuals (Otley et al., 2006).  Other 
studies report that there is no difference in measured QoL at time of diagnosis and in subsequent 
measures several years later, suggesting that time to adjust to treatments and to the disease did 
not improve QoL for the patient (Han et al., 2005).  Kalafateli and colleagues (2013) posit that 
duration of disease has no impact on scores reported on the IBDQ and measures of QoL, and is 




more likely to develop the longer an individual experiences the disease, potentially reducing 
quality of life (Casellas, Lopez-Vivancos, Casado, & Malagelada, 2002).  The extent to which 
IBD patients believe medication is controlling their high, disease activity is positively predictive 
of QoL (Rochelle et al., 2013; Faust, Halpern, Danoff-Burg & Cross, 2012).   
Chronic illnesses can interrupt life trajectory to such an extent for its sufferers that it has 
been conceptualized as a biographical disruption (Bury, 1982).  A biographical disruption refers 
to the jarring impact that a chronic illness has on an individual’s level of function and ability to 
remain active in their daily life (Williams, 1984).  Williams’s 1984 suggests that a diagnosis of a 
chronic illness changes the way in which an individual constructs their life narrative.  It requires 
the individual to construct their past, present and future identities in a way that responds to 
physical and psychosocial limitations that may be a result of their illness.  Individuals with IBD 
who maintain greater levels of normative functioning have higher levels of QoL than individuals 
who experience a disruption in their daily living (Rochelle & Fidler, 2013).  Research suggests 
that it is important for individuals with IBD to project (even if what they are experiencing is 
vastly different) an appearance that their normal functioning has been minimally impaired, as the 
maintenance of a daily routine is associated with greater control over their illness, and higher 
QoL (Rochelle & Fidler, 2013).  The longer the duration of a chronic illness, the more 
biographical disruptions can occur, shifting perspectives pertaining to an individual’s disease and 
their QoL (Paterson, 2013).   
Additionally, the Shifting Perspective Model suggests that as an individual experiences 
shifts in the severity and symptoms of chronic illness, they also shift in their levels of QoL and 
their ability to cope effectively (Paterson, 2001).  The model posits that a struggle with a chronic 




At times, the illness is at the forefront of attention, most commonly when the physiological 
symptoms are severe or are perceived as severe.    Perception of the illness is vital to the 
relationship an individual has with their disease, and can strongly influence how their 
psychological adjustment to the illness progresses (Graff et al., 2009).  The longer an individual 
copes with a chronic illness, perceptions and perspective might also change as a result of life 
experience.  Perceptions also shift continuously based on disease severity and individual’s 
physiological and psychological adaptation to their pain and experience (Paterson, 2001).     
Qualitative data was collected in an open-response format on several questions in this 
survey, and suggests that this model is particularly relevant to our population.  Individuals often 
noted that their responses on item measures would have looked dramatically different if they had 
answered during their worst flare-ups.  A “flare-up” of the disease, which is a sudden increase in 
severity of symptoms that can result in prolonged hospitalizations and rigorous courses of 
medications to try and calm down the inflammation in the system (Mackner & Crandall, 2005).  
This suggests that great oscillation can occur between positive and negative reports of QoL given 
the status of the disease, which could have impacted the results of this study.  In order to garner 
the most accurate picture of relationships between disease severity, internalizing symptoms, 
medication compliance, and QoL, research in the future should seek participants with full-blown, 
active IBD symptoms.  This will represent what the greatest needs are for a participant when 
their illness is at its most impactful state.  Having this information can contribute to how we 
construct treatment plans for patients with IBD as we seek to enhance their QoL.    
Internalizing Symptoms and IBD 
 A widely cited study, referred to as the Manitoba IBD cohort, has highlighted some of the 




colleagues (2008), suggest that individuals with IBD have a twofold increased risk of developing 
a lifetime diagnosis of depression than non-disease controls.  Individuals with IBD also 
experience significantly higher rates of anxiety and stress than do normal controls, both of which 
are associated with an exacerbation of disease severity (Berrill et al., 2013, Maunder, 2005).  
Gray and colleagues (2011) found evidence to support the impact of addressing internalizing 
symptoms, such as anxiety and depression, in improving rates of medication adherence in the 
adolescent, IBD patient population.  In targeting the reduction of these psychological symptoms, 
adolescents are better able to overcome barriers to medication adherence (Hommel et al., 2008).  
Barriers to medication adherence potentially impacted by internalizing symptoms might be 
decreased attention to details, such as forgetting when to take one’s medication, as well as what 
dosage to consume.  The link between internalizing symptoms and IBD can further be explained 
in terms of neurological connection to the gastrointestinal tract.    
The brain-gut axis, or relationship between psychological, sociological, and biological 
symptoms, appears to play a significant role in disease management for individuals with IBD 
(Drossman, 2005).  There is a relationship between internalizing symptoms, state of colonic 
mucosa, the inflammatory response, and the hypothalamic-pituitary-adrenal axis (HPA) (Grover, 
Herfarth & Drossman, 2009).  There is a bidirectional relationship between the brain and the gut, 
and researchers now suggest that dysfunctional microbiota in the intestines can contribute to the 
development of mood disorders, such as anxiety and depression (Foster & McVey Neufeld, 
2013).  Having a mental disorder prior to diagnosis can also increase the chances of disease 
relapse, as can an ongoing mental disorder during the course of the disease (Kessler et al., 2003).  




diagnosis of IBD, while others develop psychological symptoms after the manifestation of the 
physical IBD symptoms.     
Physical symptoms of IBD highly impact psychological and psychosocial adjustment for 
IBD patients, however, medical practitioners can often miss this connection (Pallis, et al., 2002, 
Knowles et al., 2015).  Belief in having little control over the course of their disease has been 
associated with higher rates of depression of individuals with IBD (Rochelle & Fidler, 2013; 
Dudley-Brown, 2002).  Depression has shown to reduce patient response to medications, 
increasing rates of relapse (Knowles et al., 2015).  The rates of depression for individuals with 
IBD increase as disease symptoms worsen, suggesting a cyclical pattern of physical and 
psychological symptoms (Maunder, 2005).  A link exists between depression and poor 
nutritional intake for individuals with IBD, and can be heightened by avoidance of food or 
negative relationships with food (Knowles et al., 2015).  Poor nutrition can increase the 
likelihood of extraintestinal manifestations, or complications spreading to other bodily organs, 
occurring for individuals with IBD (Patil & Cross, 2013; Veloso, 2011).   
Depression has also been identified as one of the greatest predictors of QoL within 
individuals in the IBD community, along with rates of active disease (Gomez-Gil et al., 2008).  
Individuals who report that their illness is associated with serious, long-term consequences, tend 
to have difficulty with healthy expression and exhibit maladaptive coping strategies (Jones, 
Wessinger, & Crowell, 2006).  Difficulty with emotional expression and representation has been 
associated with poor psychological adjustment rates, slower levels of recovery, and a high 




Higher rates of anxiety within these populations and can be detrimental to symptom 
management, which can reduce QoL (MacPhee, Hoffenberg & Feranchak, 1998; Rochelle & 
Fidler, 2013).  In a study examining neural pathways and responses to stressors using fMRI 
technology, individuals with Crohn’s disease were shown to have a weaker habituation to stress 
than individuals in the general population (Agostini et al., 2013).  Habituation to stress is seen as 
a protective factor for the body to decrease the stress response and prevent over-activation of the 
sympathetic and parasympathetic nervous systems.  Researchers also suggest that there might be 
a shift in neuronal response to microbiota in patients with IBD that is associated with stress and 
anxiety (Knowles et al., 2015).  Bacterial lumen first contacts sensory neurons, and these sensory 
neurons synapse with enteric motor neurons (Foster et al., 2013).  Enteric motor neurons are vital 
in impacting intestinal motility (Foster et al., 2013).  The sensory neurons are less excitable in 
patients with IBD, suggesting that enteric nervous system neurons can have electrophysiolocial 
responses to gut bacteria.  This also suggests that the brain can alter responses based on gut 
microbiota, also potentially explaining the association with mood disorders and the gut (Foster et 
al., 2013; Agostini et al., 2013).               
The elevated levels of depression and anxiety, and decreased reported QoL present in the 
IBD population suggest a need to discover effective methods of coping with the associated strain 
of the illness.  Research suggests that elevated levels of depression in this population can 
increase rates of morbidity and mortality, and can result in a less optimistic prognosis for patients 
(Persoons et al., 2005).  There is also evidence to suggest that depressed individuals experience 
reduced cognitive functioning, which might contribute to forgetting to take one’s medication, or 
ingesting the wrong kind of medication (DiMatteo, Lepper, & Croghan, 2000; Morís, 2014).  An 




highlights some of the common maladaptive coping factors associated with both physical and 
physiological diseases (pessimism, catastrophizing thoughts, noncompliance of treatment plan) 
(Ringel & Drossman, 2001).    
Early research regarding the origin of the disease initially cited stress as the cause of the 
illness, however, it was later established that stress and anxiety are exacerbating factors to an 
already active, biologically-based disease (Garrett, Brantley, Jones, & McKnight, 1991; Graff et 
al., 2009).   This distinction was vital to the prognosis and course of treatment that 
gastroenterologists would give their patients, as well as impacting the direction of future research 
investigating the etiology of the disease.  It is apparent that depression, anxiety and stress can be 
exacerbating factors of IBD, in addition to the biological course each patient experiences 
(DiMatteo, 2004).   Patients with depressive symptoms experience a statistically greater number 
of relapses after a period of remission than individuals who do not experience statistically high 
depressive symptoms (Mittermaier, Beier, Tillinger, Gangl, & Moser, 1998).   
Levenstein and colleagues (2000) also asserted that active disease occurs for UC patients 
when stress levels are high, further supporting the link between UC and stress.  Levels of 
depression are also higher during periods of active disease (Graff et al., 2009).  Further research 
examining the effects of stress on individuals with IBD suggests that individuals with Crohn’s 
disease experience posttraumatic stress as a result of their illness, and that subsequent studies are 
needed to determine the impact of their experience, as posttraumatic stress is a widely accepted 
threat to an individual’s overall well-being (Purc-Stephenson, 2014; Camara et al., 2008).    
Conceptualizing IBD within the Biopsychosocial Model and the Uncertainty in Illness Theory  
 The deleterious impact of stress on the body’s functioning is well-documented and well-




damaging to a body’s ability to remain at a healthy functioning level as physical stressors 
(Sapolsky, 2004).  The biopsychosocial model was developed to include multiple factors 
associated with a person’s health, suggesting that a person’s health or illness should be viewed 
from a biological, psychological, and social perspective (Shorter, 2005).  The theory is that 
within the intersectionality of these components, researchers and medical professionals can better 
understand the trajectory of someone’s health, as well as the course of their illness.  According to 
Gatchel and colleagues (2014), the biopsychosocial model “describes chronic pain and disability 
as a complex and dynamic interaction among physiological, psychological, and social factors 
that perpetuate, and even worsen, one another, resulting in chronic and complex pain 
syndromes.”  Individuals with IBD experience a unique interaction of these factors, which can 
impact the course of the disease, as well as how frequently one shifts between remission and 
relapse (Drossman, 2005).  There is literature examining the shifting disease model from which 
IBD is conceptualized (Paterson, 2001).  This literature includes examining IBD from the 
biopsychosocial model.  At an International Conference on Functional Gastroentological 
Disorders held in 2003, researchers and medical personnel first suggested the shift from the 
biomedical model to the biopsychosocial model in addressing GI disorders (Drossman, 2005).  
Disease, as it is conceptualized within the biomedical model, focuses on biological shifts in an 
individual’s tissues, cells, and potential organ malfunction.  Illness, as encompassed by the 
biopsychosocial model, includes the biological changes of disease, but also incorporates an 
individual’s subjective interpretation of feeling ill or disabled (Fleisher & Feldman, 1999).        
In addition to the overarching factors included in the biopsychosocial model, an 
individual has internal and external resources that help them deal with stressors they encounter.  




forward against the challenges of their illnesses (Camara et al., 2011).  Internal resources include 
personality factors relating to hardiness, optimism, personal control and disclosure, which all 
impact an individual’s ability to adaptively encounter the obstacles associated with their illness 
(Flett, Baricza, Gupta, Hewitt, & Endler, 2011).  External resources for dealing with stress 
include relationships, social ties, and social support (Penninx, Kreigsman, van Eijk, Boeke, & 
Deeg, 1996).  In the vein of chronic illness and health management, strong social support has 
been linked to faster recovery rates and fewer medical complications, lower mortality rates, and 
less distress in the face of chronic and terminal illnesses (Straub, 2012; Koloski, Talley, & 
Boyce, 2002).   
The Impact of Perceived Social Support for Individuals with IBD 
Social support can be defined as any aid, encouragement, and benevolence available 
through relationships and environment (Camara, Lukas, Begre, Pittet, & van Kanel, 2011).  The 
psychological benefits of social support in helping individuals cope with a variety of chronic 
illnesses are well-documented (Gallant, 2003).  The need to match the growing population of 
affected individuals with adaptive coping strategies and social support becomes clearer as the 
rates of psychological trauma associated chronic illnesses also increase (Camara et al., 2011).  
Benefits of providing social support for individuals with chronic illnesses include greater 
positive emotions, better moods, and higher perceived control (Uchino, 2006).  Individuals who 
have a greater support system tend to cope with physical and psychological symptoms more 
effectively than individuals who do not, and also report higher levels of overall QoL (Sewitch et 
al., 2001).   
PSS can moderate stress in addition to having health-related benefits outside of regulating 




PSS is particularly influential in impacting health-related outcomes.  Conversely, low PSS is 
correlated with poor health-related outcomes, more serious prognoses, and potentially higher 
rates of morality (Camara et al., 2011; Reblin & Uchino, 2008).  Individuals with IBD often 
isolate themselves from friends and family, who are vital sources of social support, feeling as 
though they do not understand the struggles they experience with their disease (Purc-Stephenson, 
2014).  Social support can significantly help individuals with IBD cope with the physical 
symptoms of the illness, as well as the psychological and emotional impact of the disease 
(Camara et al., 2011; Donoghue & Siegel, 2000).  A vital component of seeking social support 
for the IBD community lies in the willingness to open up to a group or an individual about the 
illness, as well as having access to a support network that can provide information and 
acceptance (Carlsson, Bosaeus, & Nordgren, 2003).  Individuals with IBD feel a strong 
connection to others with their illness, feeling as though they have community that is free of 
stigma.  There is a consistent pattern of individuals with IBD to seek out others who have their 
disease through support groups, online communities, and medical appointments (Purc-
Stephenson et al., 2014, Knowles & Mikocka-Walus, 2014).  There is currently a dearth of 
literature that discusses the impact of social support in the IBD population; more research is 
necessary to understand the benefits social support can potentially provide for this community 
(Purc-Stephenson et al., 2014). 
A theoretical model that incorporates chronic illness characteristics and the benefit of 
social support is the uncertainty of illness theory (UIT) (Mishel, 1990).  This model addresses 
what individuals with IBD struggle with during the course of their illness, aligning with the 
physical and emotional consequences of unpredictability in chronic disease progression.  The 




including the diagnostic period, the treatment phase, or in addressing an acute illness with 
worsening symptoms (Mishel, 1988).  Mishel (1990) generated the reconceptualized uncertainty 
in illness theory (RUIT) in order to address the experience of chronic illness and living with a  
continuous process of uncertainty rather than a finite period of time as her previous model 
addressed.  Uncertainty, as conceptualized by this model, is the inability to determine or foresee 
illness-related complications of events (Mishel, 1990).  The uncertainty in IBD inhibits some 
patients from engaging in the construction of a new, cognitive schema as it pertains to their 
identity as person with a chronic illness (Mishel, 1990).  The difficulty of redefining one’s 
identity in the context of a chronic illness, is that the uncertainty of symptom severity can result 
in a wide spectrum of patient QoL.  For example, on one end of the spectrum patients may be 
hospitalized during severe disease phases, but, on the other end of the spectrum, they can also 
resume their somewhat normal, daily routines when their symptoms are under control.  Due to 
this uncertainty, it is difficult for individuals to plan life events around the state of their physical 
health (Camachio, Verstappen, & Symmons, 2012).  The physical resources that are required to 
fight IBD consume a significant amount of physical and cognitive energy, and can often leave 
individuals feeling weak and depleted (Tinsley et al., 2016).  Individuals with severe symptoms 
can feel as though they have lost control of their bodily functions, which can increase feelings of 
stigmatization and embarrassment (Hall, Rubin, Dougall, Hungin, & Neely, 2005).  This 
uncertainty can create a sense of personal and social helplessness for individuals with IBD 
(Camacho, Verstappen & Symmons, 2012).  Mishel’s model (1990) suggests a method of 
management for these unpredictable symptoms through changes in cognitive schemas and 




There are three central components to Mishel’s (1990) model: 1) antecedents of 
uncertainty, 2) appraisal of uncertainty, and 3) coping with uncertainty.  The RUIT includes two 
additional concepts, which include self-organization and probabilistic thinking.  This model is 
designed to explain the experiences of an individual living with a remitting-relapsing disease, 
with the potential for relapse always present (Mishel, 1990).  The RUIT suggests that although 
uncertainty of one’s illness is difficult as the individual adjusts to their diagnosis, but, in time, 
there is personal growth that can occur through this process (Mishel, 1990).  
 The appraisal of uncertainty within the RUIT model refers to the ability to attach a 
positive or negative value to the uncertainty of the illness.  This appraisal can further be 
conceptualized to explain individuals who view their illness as a threat versus those who can 
view the experience as an opportunity for growth (Mishel, 1990).  In the coping portion of the 
model, if an individual is coping with an appraisal of uncertainty base on a perception of threat, 
they may engage in activities that potentially decrease management and predictability of 
symptoms.  If an individual believes in the potential for positive growth even in the face of 
uncertainty, they will be more likely to engage in activities that are biopsychosocially adaptive 
within the context of unpredictability (Mishel, 1990).  The addition of self-organization, or the 
restructuring of one’s guiding life principles, allows for an integration of uncertainty into a new, 
positive pattern of living (Mishel, 1990).  Hence, a new cognitive schema is created in which the 
individual integrates the uncertainty of their illness into their life, also allowing them to 
concurrently construct a meaningful identity (Mishel, 1990).  Individuals who view their illness 
experience as an opportunity for growth tend to be less negatively impacted by external events 





 Mishel (1990) asserts that strong social support and connection with ‘similar others’ can 
contribute to viewing an illness in a more positive light, which can then lead to an opportunity 
for the illness to become an opportunity for growth.  Similar others, or other individuals 
suffering from the same illness (or related illness), can provide a number of resources to other 
individuals experiencing their disease, including: information, encouragement, and effective 
strategies they have obtained from experience with the illness.  Disease severity and symptom 
stability are contributing factors in levels of uncertainty experienced by patients.  These factors 
are considered to antecedent factors in the RUIT model (Mishel, 1990).  Erratic disease patterns 
contribute to feelings of long-term uncertainty and feelings of hopelessness. 
The fact that the onset of IBD is, on average, fairly early in an individual’s life, 
individuals are forced to live with an unpredictable disease course and a potentially significantly 
reduced quality of life for decades.  There is often a psychological strain that results from the 
endurance of this symptom management for such a long period of time, that it often requires 
patients to seek some source of social support to aid in coping (Graff et al., 2009).  The 
utilization of the RUIT could help patients focus on shifting the perspective of their illness as a 
deficit and begin to see it as an advantageous chance to focus on growth and development, 
especially in terms of interpersonal relationships and social support.   
Rates of depression and anxiety are commonly much higher in chronic illness populations 
in comparison to the average population, increasing the need for social support to help manage 
their psychological distress (Graff et al., 2009).  We have discussed the relationship between 
IBD and greater prevalence of internalizing symptoms, such as depression, anxiety and stress 
(occurring in large part due to loss of control and autonomy for patients), but we have not 




the IBD population that are also battling higher levels of anxiety and depression tend to have 
longer, more severe flare ups than individuals who do not suffer from high levels of anxiety and 
depression, increasing spontaneous relapse rates.  Levels of depression and anxiety can 
potentially be easier to manage if an individual has social support and resources to help attenuate 
the effects of said psychological distress (Camara et al., 2011).   
Research examining the impact of support groups on reducing stress surrounding a 
chronic illness have been done in other populations coping with chronic illnesses, such as cancer 
(Stange et al., 2006).  Patients battling cancer have also been conceptualized using the 
uncertainty of illness theory, supporting its strength in addressing chronic illness concerns (Lee, 
2006).  These studies suggest that availability of community resources, access to information, 
components of acceptance, and relief of family members are all contributing factors in helping 
an individual attach a positive association to unpredictability, which helps reduce depression and 
anxiety surrounding an individual’s disease (Stange et al., 2006).  As it pertains to the RUIT, 
participation in support groups for specific illnesses is likely to reinforce community and 
understanding in a way that shows other individuals coping and thriving with a chronic illness 
(Kagee, & van der Merwe, 2006).  Studies suggest that individuals with chronic illnesses who 
perceive higher levels of social support tend to manage this depression and anxiety surrounding 
their illness more effectively (DiMatteo, 2004).  Similarly, it is possible that individuals with 
IBD whose depression/anxiety is better managed by social support are also better able to manage 
their physiological symptoms (DiMatteo, 2004; Mittermaier et al., 2004) 
IBD and other related GI disorders have been overlooked in social support literature, 
further highlighting the need to examine PSS with the intended study (Crane & Martin, 2004; 




of adverse effects in individuals with CD, discovering that social support was one of the highest 
predictors in reducing negative outcomes associated with IBD (1.5-fold reduced symptomology 
per 1 standard deviation on social support scale, ENRICHD Social Support Inventory) (Camara 
et al., 2011  
Purpose of Study 
This study had two major aims; first, to examine whether or not PSS acts as a mitigating 
factor for levels of anxiety and depression for individuals with IBD.  Although chronic illness 
literature has established PSS as beneficial for anxiety and depression, this literature has not been 
looked at within the IBD patient population specifically.  The second aim of the study was to 
assess whether PSSt moderates the relationship between depression and medication adherence 
within the IBD patient population.  Research suggests that depression reduces rates of 
medication adherence in chronic illness populations, but PSS has not been examined as a 
potential moderating variable in IBD-related studies (Camara et al., 2011).         
Consequently, 5 research questions were investigated in this study: 
Research Question 1:  
Do levels of perceived social support predict disease severity above and beyond 
internalizing symptoms, medication adherence and QoL?   
Research Question 2:  
Does perceived social support moderate the association between IBD disease severity and 
internalizing symptoms (depression, stress, and anxiety) for individuals diagnosed with IBD? 
Research Question 3: 
Does perceived social support moderate the association between IBD disease severity and 




Research Question 4: 
 Does depression moderate the association between disease severity and medication 
adherence?  
Research Question 5:  









This study used a cross sectional design to examine the relationship among IBD disease 
severity on various physical and psychological outcomes, as well as illness related attitudes.  
This study used a convenience sample and, as such, the participants were not randomly 
selected.  The independent variables included: age, sex, IBD disease type (UC or CD), IBD 
duration, QoL (SF-36), depression, anxiety, stress, PSS, online support, and medication 
adherence.  Data were obtained via self-report questionnaires in an online survey during the fall 
of 2015.  Disease severity, as measured by the IBDQ, was the dependent variable in this study.  
Moderation analyses were conducted following the hierarchical linear regression.  
Power Analysis 
 
A power analysis was conducted to determine the number of participants needed to detect 
the expected effect size of the variables of interest in this study.  In order to determine the 
sample size necessary for adequate statistical power, G*Power was utilized with a 
specification of an a priori analysis in a linear multiple regression.  The regression included 
twelve independent variables (the number used for our study) with a set alpha level of .01 and a 
hypothesized effect size (.15).  G*Power calculated that the number of participants needed for 






 Initially, missing data was to be replaced by the mean of that variable.  However, upon 
exploration of the data, dropout, consenting but not even beginning the survey, was pronounced, 
over 50%.  Based on this discovery, these individuals were dropped and the original sample size 
decreased from 306 to 155.  The participants included in analyses still had some missing 
responses, but had answered at least one question in every scale.  
 Thirty males (19.4%) and 125 females (80.6%) who ranged in age from 19-69 years old 
(M = 37.60, SD = 12.44) participated.  More than half, 59.4%, of participants were from the 
United States, 11.6% from Canada, and 29% selected ‘other’, which included: England (n = 21), 
the Netherlands (n = 2), Scotland (n = 2), Romania (n = 1), New Zealand (n = 7), Australia (n = 
9), Singapore (n = 1), Germany (n = 1) and India (n = 1).  Participants identified as Caucasian 
(92.3%), African American (1.3%), Hispanic (1.3%), Asian (1.3%), Native American (.6%), and 
Other (3.2%).  The highest percentage of participants made an annual salary of less than $20,000 
or between $20,000-$29,000 per year (49.6% combined).  A little under half, 45.8%, of 
participants rated their disease as severe, 41.9% as moderate, and 11.6% mild.  
Procedures 
 
Participant recruitment.   
 Participants were recruited via social media forums.  The two social media forums 
utilized most heavily were Twitter and Facebook.  Individual requests were tweeted to people 
who had identified themselves as having either Crohn's disease or ulcerative colitis.  Individuals 
identified their connection to IBD on Twitter by including their disease in their username or in a 
caption hashtag visible on their profile.  On Facebook, a general post was made on the 




These support groups were identified in doing a general search on the site using keywords 
including: Crohn's disease, IBD, ulcerative colitis, ileostomy, or colostomy.  Finally, the prompt 
and link to the survey was distributed via email.  Together these methods generated a snowball 
effect of individuals passing along the survey.   
Participants clicked on the link to the survey, which took them to an informed consent page.  
This page outlined the purpose of the study, identified relevant parties to contact with questions 
regarding the study, and a brief description of how long the following survey might take.  
Participants were allotted an unlimited time period to complete the survey and were allowed to 
step away from their computer and resume again should they need a break.  If completed in one 
sitting, the survey assessment took approximately 25 minutes.  The surveys were designed and 
administered online through the Qualtrics survey package, which is provided access to students 
at Colorado State University.   
Measures    
Inflammatory Bowel Disease Questionnaire 
The IBDQ was administered to assess disease severity of symptoms for participants with 
Inflammatory Bowel Disease (IBDQ; Guyatt et al., 1989).  The IBDQ consists of 32 questions 
broken down into 4 distinct subscales, which include bowel related symptoms (10 items), 
systemic function (5 items), social function (12 items), and emotional status (5 items) 
(Magalhaes, Castro, Carvalho, Moreira & Cotter, 2014). The questions are scored on a 1-7 Likert 
scale, with 1 indicating the highest severity of the disease.  Although this has not been noted in 
literature, the counterintuitive scoring system (that lower scores indicate higher disease severity) 
used by the IBDQ lends itself to more complicated analysis, and might be improved with 




signified remission.  For the purpose of our study we examined severity on a continuous scale 
and simply correlated lower scores with higher severity, and higher scores with lower severity.  
The test-retest reliability of the IBDQ for Irvine (1996), ranged between α=.77-.94 and had a 
strong, consistent intraclass correlation coefficients (ICCs) of .90-.97.  Pallis (2004) also 
reviewed a national collection of data pertaining to the IBDQ, which reported the test-retest 
reliability of the English IBDQ, which yielded an (α = .72-.89).  In a cross-cultural look at the 
reliability of the IBDQ, Verissimo (2008) established an internal reliability of (α = .92), and a 
mean α = .82 for the four subscales.  For this study, the Inflammatory Bowel Disease 
Questionnaire alpha was .95. 
RAND 36-Item Health Survey 
Quality of life (QoL) was assessed with The Short Form-36 (SF-36) Health Survey 
(Hays, Sherbourne, & Mazel, 1993).  .  The SF-36 is a 36-item survey, broken down into 8 
subscales, that has been widely used to assess generic QoL health issues in individuals with 
chronic illnesses (Revicki, Rentz, Luo & Wong, 2011); Jenkinson, Coulter, & Wright, 1993).  
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries 
equal weight, and the eight scaled scores are the weighted sums of the questions in their section 
(Revicki et al., 2011).  The lower the score, the more dissatisfaction an individual has with their 
overall QoL (a score closer to 0 indicates a poorer QoL, whereas a score closer to 100 indicates a 
greater QoL) (McColl, Han, Barton & Welfare, 2004).  Bernklev and colleagues (2005) 
conducted a study examining the reliability of the separate subscales as reported through 
Chronbach’s alpha for both CD and UC, which yielded physical functioning CD (α = .85) and 
UC (α = .91), social functioning CD (α = .80) and UC (α = .81), role limitations due to physical 




.72) and UC (α = .74), mental health CD (α = .84) and UC (α = .81), energy and vitality CD (α = 
.86) and UC (α = .86), pain CD (α = .90) and UC (α = .88), and general perception of health CD 
(α = .83) and UC (α = .81).  The SF-36 is reliable and generalizable, having been utilized in 
empirical studies of more than 200 illnesses (McHorney, Ware Jr & Raczek, 1993; Ware, 2000).  
Short-Form 36 alpha was .65 in this study (subscale) alphas include: physical functioning was 
.94, role limitations due to physical health was .93, role limitations due to emotional issues was 
.87, energy fatigue was .89, emotional well-being was .89, social functioning was .90, pain was 
.90, and general health .83).  Depression, Anxiety, and Stress Scale alpha was .97 (the 
depression subscale was .94, the anxiety subscale was .91, and the stress subscale was .96) in this 
study.     
Medication Adherence Rating Scale 
Medication adherence was assessed with the MARS, a ten item, dichotomous 
questionnaire assessing compliance to prescribed medication regimens (Thompson, Kulkarni, 
Sergejew, 2000).  Thompson and colleagues (2000) generated this scale for a psychiatric 
population, and illustrated that the scale had adequate reliability (α = .75).  The scale is measured 
by self-report yes / no answers that are scored 0 / 1 respectively.  The scores will range from 0-
10, with 0 indicating a score of low medication adherence, and 10 indicating a score of high 
medication adherence (Thompson et al., 2000).  Fialko and colleagues (2008) conducted a large 
scale validation study of the MARS, yielding a lower overall alpha (α = .75) than Thompson and 
colleagues (2000).  The researchers conducted internal reliability tests of the three separate 
categories that are represented in the MARS, which include medication adherence behavior (α = 
.67), attitudes towards taking medication (α = .44), and negative side effects and attitudes to 




this study (adherence behavior scale was .75, attitude taking meds .15, body when taking meds 
.41).  Given this low reliability, a principal components analysis was conducted on the MARS 
scale.  The scale was reduced to 4 items, yielding a reliability of α = .75.  This 4 item scale was 
used in the analyses. 
Depression Anxiety and Stress Scale  
The DASS is a 42-item scale that assesses depression, anxiety and stress, and as such, is 
broken down into three, 14-item subscales (DASS; Lovibond & Lovibond, 1995).  Respondents 
are asked to use a 4-point severity/frequency scale to rate the extent to which they have 
experienced each state (depression, anxiety, stress) over the past week.   Each question is scored 
from 0 (Did not apply to me at all) to 3 (Applied to me very much, or most of the time), so that 
42 is the highest possible score on each of the three subscales (for a total of 126 on the total 
DASS).  Higher scores indicate higher rates of depression, anxiety and stress.  Multiple studies 
have shown the internal reliability of the Depression Anxiety Stress Scale, illustrating consistent 
reliability (DASS, Lovibond & Lovibond, 1995; Brown et al., 1997; Antony et al., 1998).  
Antony and colleagues (1998) reported reliability on the three separate scale, Depression (α = 
.97), Anxiety (α = .92), and Stress (α = .95).  Crawford and colleagues (2003) also reported 
reliability of the scales Depression (α = .93), Anxiety (α = .95), and Stress (α = .90).  In addition 
to being psychometrically strong, the DASS might be one of the few scales effective at 
differentiating between anxiety and depression (Page, Hooke & Morrison, 2007).  This scale was 
effective at differentiating anxiety and depression in this study.  Depression, Anxiety, and Stress 
Scale alpha was .98 (the depression subscale was .97, the anxiety subscale was .91, and the stress 




Multidimensional Perceived Social Support (MSPSS)  
The MSPSS is a 12-item scale that assesses perceptions of available social support 
(Zimet, Dahlem, Zimet, & Farley, 1988).  The overall scale is reliable, with strong internal 
consistency (α = .84).  The scale is broken down into three separate subscales that assess PSS 
from family (α = .81), friends (α =.90) and significant others (α = .83) (Zimet et al., 1988).  Items 
are answered on a 7-point Likert scale ranging from 1 (very strongly disagree) to 7 (very strongly 
agree).  Higher scores on the MSPSS indicate higher rates of PSS (Zimet, Powell, Farley, 
Werkman & Berkoff, 1990).  For this study, the MSPSS yielded an α = .97 (significant other 
subscale was α = .97, family support was α = .96, and friendship support was α = .97).   
Online Social Support 
Four questions were generated (“I seek emotional help from online support groups,” 
“Online support groups provide me with anonymity in sharing my feelings,” “I can talk about my 
problems with others online because it is often a shared experience,” and “Online support groups 
are more accessible to me given my condition”) to   examine the importance of online social 
support for participants. These questions were asked following completion of the MSPSS items. 
These questions were answered on a 7-point Likert scale ranging from 1, very strongly disagree, 
7, very strongly agree.   Higher scores on this scale (totals closer to 28) indicate greater usage 
and reliance upon online social support.  Examination of internal consistency in this study 
yielded (α = .90), supporting the retention of these questions and their utilization in correlation 
analyses.  The online support scale had a strong correlation with the MSPSS scale, which has 
been established as a reliable and valid measure of social support.  Therefore, the online support 





To begin preliminary analysis for this study, all analyses were performed in the 
Statistical Package for the Social Sciences (SPSS IBM, 2013) and, a priori, p < .05 was set 
as the level of statistical significance.  The data was then examined for missing items, which 
resulted in excluding participants from the analysis to a total of 155 for the analyses 
(Howell, 2008; Osborne, 2012).  Data were checked for accuracy and errors by the 
researcher before preliminary analyses were conducted. Descriptive statistics were then 
conducted to examine the data (Table 3).  Correlation analyses were also conducted for all 
independent variables and the dependent variable (Table 5).    
Scales were scored according to the specific instructions of the authors of each scale.  
Various scales and subscales were recoded and summed for the purpose of future analyses.  Sex 
was dummy coded (female = 0, male = 1), as was diagnosis type (ulcerative colitis = 0, Crohn’s 
= 1).  First, descriptive plots and statistics including range, mean, standard deviation, skew and 
kurtosis were performed to examine the normality of each variable in our study.  There were no 
apparent issues with normality based on the results of the descriptive statistics.    
Next, the assumptions of regression procedures were examined.  We studied several 
behaviors relating to similar constructs in this study, and as such, there was a probability 
that there was high correlation amongst variables.  Collinearity relates to the potential 
adverse effects of correlated independent variables on the estimation of regression statistics 
(Kraemer & Blasey, 2004).  Multicollinearity refers to the collinear relations among more 
than two variables.  When multicollinearity becomes an issue, the model may potential 
become unreliable as the measures are examining the same construct (Kraemer & Blasey, 




  when the regression coefficients are not statistically insignificant, or when the regression 
coefficients would change significantly should certain independent variables be eliminated 
(or inserted) from the model.  SPSS computes tolerance (1- R2) for evaluation in the analysis.  
Multicollinearity is suggested to be a problem if the tolerance output is less than 1- R2.  
These methods of detecting multicollinearity were utilized in examination of the regression 
output.  The variables were centered for the hierarchical regression as a result of detecting 
several potential issues with multicollinearity (Table 3.).  
Then, the reliability of each measure was examined.  Subscales as well as total scores for 
each predictor variable was tested in reliability analysis.  Reliability analyses were conducted for 
each measure to assess the extent to which all the items measured the same construct, and 
therefore, connected to the inter-relatedness of the items within the test (Tavakol & Dennick, 
2011).  Should a scale render poor reliability, further examination was necessary to see whether 
or not items needed to be dropped from the scale, whereby improving internal reliability.  The 
internal consistencies for measures used in the study ranged from .55 to .97; subsequently, two 
scales were further examined based on findings of poor reliability.  The ‘General Health 
Perceptions’ subscale was dropped in the SF-36 scale (with the lowest alpha, .83), increasing the 
overall Cronbach’s alpha from .65 to .73.   
The Medication Adherence Rating scale had poor reliability with an alpha was .55, 
further investigation was conducted to see if using one of the subscales would be more reliable 
with this population.  This is the first time the MARS has been tested for reliability within the 
IBD population, and was originally designed to assess a psychiatric population.  The first 
subscale, four items measuring medication adherence behaviors, yielded the highest alphas of the 




 A PCA identifies factors, or principal components, that account for the most variance.  This 
helps decipher what factors are the most salient in the measure for that population.  In 
completing the analysis on the 11 items in the MARS scale used in the study, the first principal 
components yielded eigenvalues over 1, and accounted for approximately 65% of the variance in 
responses.  The scree plot was also consistent with this 4 item selection, as the descension point 
stopped at the fourth item and transitioned into what is referred to as rubble items in the 
remainder of the figure.   
A correlation analysis was conducted between the independent and dependent variables 
as a way to avoid potential confounding variables.  There was evidence of online support and 
disease type as a possible confounding variable in this study, because both were significantly 
correlated with the dependent and independence variables.  These variables were subsequently 
controlled for in the hierarchical regression as well as the moderation analysis.  Following this 
step, the hierarchical regression was designed to determine the order of variable inclusion. As 
the hierarchical regression was planned, we entered individual factors in the model first, and 
then included social support and medication adherence.  Data were collected on one occasion 
for each participant, which all were single, independent samples.  Upon running each analysis, 
scatter plots were also examined to check if each independent variable illustrated a normal 
distribution pattern with the dependent variable.  
Statistical analysis.  
A hierarchical linear regression (HLR) was conducted for the purposes of this study.  
Although the study is exploratory in the sense that there is limited literature regarding the topic, 
it is not exploratory in a statistical sense.  Therefore, a hierarchical linear regression was used 




behaviors, and was, therefore, appropriate for this study.  A written model of the regression 
equation used for this study can be viewed below: 
Y1 = a + b1X1 + b2X2 + b3X3 + b4X4 + b5X5 + b6X6 + b7X7 + b8X8 + b9X9 + 
b10X10 + b11X11 
 
For the purposes of this study, Y1 = symptom severity as measured by the IBDQ, X1 = age, 
X2 = sex, X3 = disease diagnosis, X4 = disease duration, X5 = QoL, X6 = depression, X7 = 
anxiety, X8 = stress,  X9 = perceived social support, X10 = online support, and X11 = medication 
adherence.  The regression correlation coefficients for the independent variables used in the 
study are represented via b1-b11.  A regression analysis was used to obtain predicted values of 
the dependent variable given the specific influence of the independent variables.  The R2 was 
then examined in order to establish the amount of variance accounted for in the dependent 
variable as a result of the regression with the independent variables. 
Variables were then entered hierarchically into the analysis and chosen based on the 
multicollinearity analyses and examination of confounding variables. As sociodemographic 
variables can potentially confound the relationship between the independent variables and 
disease severity, the dependent variable, they were tested first in the regression: age and sex.  
The variables entered second in the analysis were disease related variables: disease type 
(dichotomous variable, 0 = ulcerative colitis, 1= Crohn’s disease), disease duration (in years), 
and QoL.  The variables entered third in the analyses were internalizing symptoms: depression, 
anxiety and stress. The variables entered fourth in the analysis were PSS measures as well as 
online support; the variables entered fifth in the analyses was medication adherence.  Disease 
type and online support were identified as potential confounding variables.  As such, an 
interaction term created by the product of two variables was added as the sixth model in the 




Variables entered into the HLR were centered to avoid multicollinearity.  In addition to 
protecting against multicollinearity, suppressor variables were also considered.  Suppressor 
variables are those that enhance the effects of other variables in the set of independent/predictor 
variables, potentially showing that they account for more of the predicted variance in the 
dependent variable than they actually do (Tabachnick & Fidell, 2013).  There was an indication 
of the presence of social support as a suppressor variable in each progressive model, as it also 
did not present with opposite signs in the zero-order correlation output compared to the β 
weight and semi-partial correlation output, and was consistent with correlation directions of 
previous output See Table 4.       
Finally, six moderation models were examined in SPSS.  In order to test whether the 
effect of independent variables on the dependent variable is conditional on another variable, 
moderation analyses were conducted.  Interaction terms were created to assess the combined 
effects of PSS and the full DASS scale and medication adherence on disease severity.  Product 
terms were also created to assess the combined effects of medication adherence and 
depression on disease severity, the combined effects of QoL and anxiety on disease severity, 
the combined effects of PSS and anxiety on disease severity, and the combined effects of PSS 
and stress on disease severity. The moderation, regression equations containing the 
interactions: 
Model 1-6: Y1 = b1X + b2Z + b3XZ + b0 
 
where 1.Y1 = disease severity, X = perceived social support, Z = full DASS, 2.  Y1 = disease 
severity, X = perceived social support, Z = medication adherence, 3. Y1 = disease severity, X = 
medication adherence, Z = depression, 4. Y1 = disease severity, X = Qol , Z = anxiety, 5. Y1 = 




perceived social support, Z = stress.  The moderation interaction term is achieved when the 
predictor variable (X) is multiplied with the moderating variable (Z) to form a new variable 
(XZ).  Moderation was indicated by a significant interaction term. Significant moderation models 
were then examined using the PROCESS macro provided by Hayes (2013) for the purpose of 
probing the simple slopes and visualizing the interaction.  PROCESS macro automatically 
centers variables during analyses.  We did not center variables in the initial moderation analyses 
as we did in the hierarchical linear regression model.  To eliminate superfluous analyses, the 
significant models were probed in PROCESS macro.  We ultimately probed 3, significant 
models that illustrated that the moderator variable, or the combination of the moderator variable 









 The sample consisted of 155 participants.  Descriptive analyses were conducted, as well 
as an independent samples t-test, to compare the means of the variables by diagnosis, which was 
dummy coded (ulcerative colitis = 0, Crohn’s disease = 1).  The independent samples t-test 
showed that patients with Crohn’s disease (m = 16.26) had a significantly longer duration with 
IBD than individuals with UC (m =9.05) (p < .001).  Those with CD (m = 19.86) also reported 
significantly higher rates (m = 18.51) of online social support seeking (p < .05).   Results can be 
seen in Table 2.   
Table 7 includes the results of the HLR. A regression equation was used to examine the 
extent to which sociodemographic variables (age, sex) disease related variables (diagnosis type, 
disease duration), internalizing symptoms (anxiety, depression, and stress), medication 
adherence, and PSS might explain IBD disease severity (IBDQ).  In the equation, age and sex 
were entered first. The disease-related variables, disease type (Crohn’s disease or ulcerative 
colitis) disease duration (in years), and overall health and well-being (QoL) were entered second.  
Levels of PSS and online support was entered third.  Internalizing symptoms (anxiety, stress, and 
depression) were entered fourth.  Medication adherence was entered fifth.  In order to control for 
potential confounding variables, the sixth regression model included the interaction term 
between disease type and online social support.    
Table 7. includes the results of the disease severity predictive model conducted via 
hierarchical linear regression.  The modified SF-36 scale was used for this regression, which 
featured 31 items (the General Health subscale was excluded, which included 5 items).  The 




variables accounted for 55% of the variance in disease severity.  The adjusted R2 = .50, which 
represents a medium effect size (Cohen, Cohen, West & Aiken, 2003).  Similar to the previous 
regression, the second model entered into the regression, including disease related variables was 
significant, F (5, 105) = 3.60, p = .01 (the change in significance went from p = .05 to p = .01 
with the adjusted SF-36 scale in this model), as well as the third model, which was entry of 
internalizing symptoms, F (8, 102) = 13.49, p = <.001, and the fourth model, which was entry of 
the social support variables, F (10, 100) = 11.81, p = < .001.  Findings also indicated that with 
the modified scale, QoL was now the most significant predictor of disease severity within this 
model t = -2.93, p = .004.  Stress became the second most significant predictor of disease 
severity in the model t = -2.147, p = .03.  Lower scores on the IBDQ represent greater disease 
severity, this indicates that the higher scores are on anxiety, the lower the scores on the IBDQ.  
Anxiety (sr = -.13, p = .07), and social support (sr = -.13, p = .07) were the next most predictive 
factors, but were not significant.  Age, disease type, duration of diagnosis, medication adherence, 
depression, and online support were also not significant predictors of disease severity, all ps > .1.  
Social support was a potential suppressor in this model.  See Table 4.   
After examining six moderation models, specified below, via their interaction terms in 
SPSS output, significant models were further inspected using the Process macro provided by 
Hayes (2013) to visualize the interaction and probe simple slopes.  Moderation analyses were 
performed to examine: 1) If the effect of disease severity (M = 135.02, SD = 36.34) on 
internalizing symptoms, DASS Sum, (M = 33.66, SD = 27.64) was moderated by PSS (M = 4.96, 
SD = 1.70); 2) (Table 8.), if the effect of disease severity on medication adherence (M = 16.74, 
SD = 11.68) was moderated by PSS (Table 9.), 3) if the effect of disease severity on medication 




 effect of disease severity on QoL was moderated by anxiety (M = 9.65, SD = 8.81) (Table 11), 
5) whether the effect of disease severity on anxiety was moderated by PSS (Table 12); and, 6) 
whether the effect of disease severity on stress (M = 14.21, SD = 10.66) was moderated by PSS 
(Table 13).  The interaction terms for the second moderation model (p > .74) and third 
moderation model (p > .46) were not significant.  Thus, neither social support nor depression 
moderated the effect of disease severity on medication adherence.   
When the original QoL scale was used for Moderation Model 4, it did not yield a 
significant interaction term (p = .19).  However, the analyses were run a second time after the 
‘General Health’ subscale was dropped to increase the scale’s reliability.  The interaction term 
was not found to be significant (p = .12), but the overall model was significant (F (3, 127) = 
4.97, p = .003, R2 = .11.  Although the interaction term did not yield a significant effect, this 
model was probed in process due to the change that occurred in using the modified Sf-36 scale.  
Probing Moderation Model 4 resulted in significant moderation results at the 50th and the 75th 
percentile of the moderator between disease severity and anxiety, which will be discussed in 
more detail below.  Moderation Model 1 (F (3, 121) = 44. 59, p < .001, R2 = .53, Moderation 
Model 5 (F (3, 124) = 39.91, p < .001, R2 = .49, and Moderation Model 6 (F (3, 121) = 29.40, p 
< .001, R2 = .42 also had significant interaction terms. 
Moderation Model 1 
The slopes of [Y on X] internalizing symptoms on disease severity were significantly 
different from zero and from each other for the 25th percentile of the moderator (b = -.54, SE = 
.06), t = -9.26, p < .001, 50th percentile of the moderator (b = -.43, SE = .05), t = -8.34, p < .001, 
and 75th percentile of the moderator (b = -.37, SE = .06), t = -5.91, p < .001.  Findings from this 




pronounced at lower levels PSS (Figure 1).   
Moderation Model 4 
The slopes of [Y on X] QoL (the modified scale) on disease severity was not significantly 
different from zero and from each other for the 25th percentile of the moderator (b = -.06, SE = 
.04), t = -1.75, p = .08.  However, significant results were found in the model at the 50th 
percentile of the moderator (b = -.08, SE = .03), t = -2.38, p = .019, and 75th percentile of the 
moderator (b = -.13, SE = .04), t = -3.11, p = .002.  Findings from this analysis indicate that the 
effect of disease severity on QoL was more pronounced at higher levels of anxiety (Figure 2).   
Moderation Model 5 
The slopes of [Y on X] anxiety on disease severity were significantly different from zero 
and from each other for the 25th percentile of the moderator (b = -.16, SE = .02), t = -8.55, p 
<.001, 50th percentile of the moderator (b = -.13, SE = .02), t = -7.43, p < .001, and 75th 
percentile of the moderator (b = -.12, SE = .20), t = -5.60, p < .001.  Findings from this analysis 
indicate that the effect of disease severity on anxiety was more pronounced at lower levels of 
perceived social support (Figure 3) 
Moderation Model 6 
The slopes of [Y on X] stress on disease severity were significantly different from zero 
and from each other for the 25th percentile of the moderator (b = -.18, SE = .03), t = -7.00, p < 
.001, 50th percentile of the moderator (b = -.15, SE = .02), t = -6.33, p < .001, and 75th percentile 
of the moderator (b = -.13, SE = .27), t = -4.56, p < .001.  Analysis findings indicate that the 








IBD causes physical and psychological disruption for individuals who battle the disease 
(Keeton, Mikocka-Wallus, & Andrews, 2014).  Previous research illustrates a relationship 
between IBD disease activity and a reduced QoL.  Research also suggests that greater disease 
severity is associated with higher levels of anxiety and depression, with low rates of medication 
adherence (Greenley et al., 2015).  Perceived social support is an important contributor to 
adjustment factors associated with IBD (Schwenk, 2014).  This examined the extent to which 
perceived social support moderates the association between disease severity and QoL, and 
between disease activity and various internalizing symptoms (depression, anxiety and stress).  
There are no published studies that have examined these questions in an IBD population.  This 
study also examined the factors that potentially moderate the relationship between disease 
severity and medication adherence, depression and perceived social support within this 
population.  It is important to note that, while this study looked at moderating relationships, it 
was, ultimately, an exploratory study.  This study relied on a convenience sample drawn from 
online sources.  A more representative sample selected randomly from the IBD population would 
allow this study’s findings to generalize to that population. 
Research concerning the use of online support systems for individuals with chronic 
illnesses is novel.  According to Yao and colleagues (2015), stigmatized patients with chronic 
illnesses who seek online support also experience improved levels of QoL.  This research 
suggests that those who perceive themselves most excluded from social networks benefit the 
most from online support systems (Yao, Zheng, & Fan, 2015).  Individuals with IBD experience 




IBD patient population from seeking support outside of the home may be the physical 
restrictions imposed upon them due to the severity of their symptoms.  Speaking anecdotally as a 
therapist who works closely with chronic illness populations, and those with GI disorders in 
particular, cancellation rates due to unpredictable disease complications are quite high.  This is a 
difficult hurdle to overcome in achieving therapeutic goals; it is difficult to accomplish 
meaningful progress with clients when attendance is sporadic.  Online support provides the 
convenience of accessing connection and social support from one’s home, or hospital bed.  It is 
not uncommon for individuals to post photos of themselves in their hospital beds on these 
Facebook support group pages, to which they get an overwhelming response of positive, caring 
messages from others within the IBD patient population.  Being able to connect with others who 
understand their pain and the impact of this illness, provides a sense of solidarity and 
understanding that they cannot find with anyone else in their social network.  Due to the 
relationship that exists between this patient population and online support seeking behavior, 
research pertaining to the efficacy and effectiveness of online therapeutic interventions is an 
important direction for treating these individuals.  Sessions conducting acceptance and 
commitment therapy (ACT) could be constructed and broadcast through online forums, and 
individuals could join in for group sessions via Skype or other video chat options available from 
their computer.  This therapy option could increase the rates of patient participation in sessions, 
which, by extension, could potentially improve their quality of life and help in reduction of 
internalizing symptoms.  
Perceived Social Support 
Findings indicated perceived social support was significantly correlated to disease 




 they reported their disease activity to be.  When higher rates of perceived social support were 
reported, higher levels of stress, anxiety and depression were also reported.  Previous evidence 
suggests that higher perceived social support correlates with an overall decrease in distress 
related to inflammatory bowel disease (Rini, Jandorf, Valdimarsdottir, Brown & Itzkowitz, 
2008).  This study’s findings illustrate that perceived social support also helps moderate the 
association between disease severity and internalizing symptoms, providing greater evidence as 
to its impact on minimizing the effects of physical and psychological components of IBD.  The 
benefits provided from higher perceived social support contribute to the overall well-being of an 
individual with IBD. These results provide more evidence as to the benefits of social support in 
managing chronic illnesses and the associated distress of unpredictable symptoms.  As 
physicians and other medical personnel interact with patients with IBD, it is important that they 
consider the positive impact of social support in helping minimize the burden of disease 
management on patients with chronic illnesses (Houtum, Rijken, Heijmans & Groenewegen, 
2015).  Houtum and colleagues (2015) discuss their breakdown of self-management tasks and 
support needs in 4 distinct categories 1) medical management (taking medications correctly, 2) 
communication with healthcare providers (visiting for appointments and asking questions), 3) 
coping with the consequences of the illness (coping with pain, emotions, and an uncertain 
future), and 4) making lifestyle choices (exercising enough, new diet).  Reduced anxiety 
surrounding IBD can further help reduce hospital and office visits, can increase levels of 
medication adherence, and can decrease the potential for the occurrence of extraintestinal 
manifestations (EIMs) (Patil et al., 2013; Veloso, 2011).  
Previous literature suggests that social support might be important for psychosocial 




help patients manage their disease more effectively.  Individuals who rate higher levels of 
perceived social support in previous studies have also associated that support with having greater 
control over their illness (Joachim, 2002; Rochelle et al., 2013).  One of the predictors of high 
anxiety in the IBD population is loss of control that ensues with chronic, relapsing-remitting 
symptoms (Sandborm, 2014).  A factor that helps them feel more in control can benefit them a 
great deal.  Perhaps this also helps explain the allure of online social support—one has more 
control over the interactions when they are conducted online.  Individuals with IBD can feel 
anxious and stressed in social interactions with individuals as they never know if/when it might 
be interrupted by their disease symptoms (Taft, Keefer, Leonhard & Nealon‐Woods, 2009). The 
relationship between anxiety and stress and the severity of disease activity was found to be 
significantly impacted by perceived social support in the context of our study.  The greater the 
social support, the lower the disease severity, and the lower the levels of anxiety and stress 
(Joachim, 2002; Rochelle et al., 2013).  This suggests that perceived social support has a 
significant impact on reducing stress/anxiety and disease severity.  Social support seems to be an 
important factor in helping reduce anxiety in individuals with IBD, which is associated with 
lower disease severity (Kane, 2008; Rochelle et al., 2013).  Previous literature suggested that 
social support might be important for psychosocial adjustment in this population, and this study 
provides evidence that social support, does, in fact, help patients manage their disease more 
effectively.  Individuals who rate higher levels of perceived social support in previous studies 
have also associated that support with having greater control over their illness (Joachim, 2002; 
Rochelle et al., 2013).  One of the predictors of high anxiety in the IBD population is loss of 
control that ensues with chronic, relapsing-remitting symptoms (Sandborn et al., 2014).  A factor 




Solomon and colleagues (2012) conducted a randomized control trial to assess the 
efficacy of web-based interventions for patients with a range of chronic illnesses and conditions.  
These researchers wanted to examine the extent to which their intervention increased patient 
activity in self-management interventions (SMIs).  SMIs are strategies that patients can utilize to 
improve disease management, and include programs that help educate them about various 
aspects of their illness, help them learn ways to incorporate self-care into their routine, and that 
work to bolster confidence in their overall ability to manage their illness independently 
(Solomon, Wagner, & Goes, 2012).  These strategies are effective at increasing a patient’s 
engagement in disease-management techniques, which contributes to feelings of more control 
and stability surrounding their illness (Solomon et al., 2012).  Patients with IBD feel as though 
there should be more resources offering psychological support to help cope with the burden of 
disease management (Mikocka-Walus et al., 2013).  Mikocka-Walus and colleagues  (2013) 
assert that psychotherapy is significantly underused in the IBD population as a way to cope with 
their chronic symptoms and increase feelings of competency concerning disease management.  
Use of Cognitive Behavioral Therapy (CBT) has shown initial, positive results for IBD patients 
who attend psychotherapy sessions (Mikocka-Walus et al., 2013). However, barriers such as 
restricted physical ability seem to be preventing patients from seeking psychotherapy as a 
treatment modality.  As such, Mikocka-Walus and colleagues (2013) also suggest that online 
forms of psychotherapy and intervention may be the answer to providing IBD patients with the 
psychological support they need.       
Internalizing Symptoms 
The significant models in our study suggest that levels of high anxiety and stress are 




associated with lower levels of stress and anxiety (Rochelle et al., 2013).  Although the full 
DASS scale showed a significant relationship with disease severity, when depression was 
isolated from the scale, it was not found to be a significant predictor of disease activity.  Hence, 
the two most prevalent predictors were stress and anxiety.  It is unclear, based on previous 
research, which is more impactful on which—whether individuals with high anxiety develop 
more severe symptoms, or, that people who already have very severe symptoms experience 
extreme stress/anxiety as a result of the complications and disruptions caused by their illness.  
Therefore, there is evidence that lower levels of anxiety were associated with lower levels of 
disease severity and overall QoL.   
Although the absence of a diagnostic interview prohibited determination of clinical 
diagnoses, our study highlights the importance of perceived levels of disease severity and overall 
well-being as it pertains to anxiety and stress, and therefore, the importance of perceived social 
support.  How the participants perceive pain and associated support impacts their levels of stress 
and anxiety (Rochelle et al., 2013).  This is consistent with the reconceptualized uncertainty in 
illness theory (RUIT), suggesting that those who view their illness as a continuous, unpredictable 
threat will remain highly anxious about its prognosis (Mishel, 1990).  Those who view their 
illness as a potential for post-traumatic growth and opportunity will be less likely to associate the 
symptoms with such distress (Mishel, 1990; Calhoun & Tedeschi, 1989; Calhoun, Cann, 
Tedeschi & McMillan, 2000).  Future research examining post-traumatic growth and disease 
severity might continue to inform this theory and its relationship to IBD.      
Medication Adherence 
Although perceived social support was found to attenuate levels of stress and anxiety 




medication adherence based on levels of disease severity.  The medication adherence scale was 
dichotomous and did not provide a wide range of options to show where individuals fall on a 
continuum of taking their medications, whereby reducing potential variability in the study of 
adherence patterns.  This does not allow us to examine where on the spectrum of medication 
adherence individuals with higher rates of disease activity and internalizing symptoms fall.  
There are several potential explanations that might account for our results related to medication 
adherence.   
Medication plans are developed with the intent of helping patients with IBD manage and 
control their symptoms, but can sometimes result in more negative side effects than positive, 
leaving individuals with IBD feeling more frustrated and hopeless in the attempt to manage and 
control their symptoms.  Controlling symptoms for an IBD patient might result in less diarrhea, 
greater absorption of nutrients, lower levels of blood loss and anemia, more control of 
incontinence, and more energy to engage in daily tasks that have been restricted with the illness 
symptoms (Vavricka et al., 2015).  Effective treatment plans also lessen the pain that individuals 
with IBD experience, and may prevent against the development of EIMs, allowing for an 








This population was also recruited from support groups and individuals active in 
discussing their disease experience.  The support and online network of individuals on these 
forums could also impact how individuals perceive the benefits of their medication plans.  It is 
common for individuals to publish their personal experiences with various medications with 
others online, providing information for others wanting to know what medications are available 
and working most effectively (Coulson, 2015).  People have the opportunity to ask questions 
pertaining to the maintenance of this disease that is beyond the scope of doctors and nurses 
(Coulson, 2015). This might make an individual more hesitant to even attempt taking this 
medication.  Individuals readily discuss treatment plans, new medications, medication 
complications, and various management techniques on these forums.  Facebook, Twitter, and 
Youtube have become a valuable resources for people to connect with others who are struggling 
with this disease, perhaps providing higher levels of perceived social support (Frohlich & 
Zmyslinski-Seelig, 2012).  However, we did not find that perceived social support was predictive 
of medication adherence in our model.  Perceived social support did not impact levels of 
medication adherence in our study, suggesting that more investigation is needed to fully 
understand what increases the likelihood of patients with IBD to adhere to their treatment plans.  
Although this study yielded significant results contributing to the understanding of the role of 
perceived social support in mitigating disease symptoms and internalizing symptoms in 
individuals with IBD, this study had numerous limitations.  First, instead of using a medication 
adherence scale with items that only allowed for a dichotomous choice, it would be more 




was originally designed for a psychiatric population, and not for individuals with chronic, 
physical illnesses.  A more reliable measure that was constructed for individuals with IBD or 
other chronic, autoimmune disorders might provide for a more precise understanding of the 
interaction between medication adherence, disease severity, and internalizing symptoms.  
Previous studies examining IBD and medication adherence suggest that this population is at high 
risk for medication non-adherence (Ediger et al., 2007).   
This survey was conducted through via online questionnaire.  Participants clicked on the 
posted survey link and were directed to the consent page on the questionnaire.  Some participants 
commented that they had technical difficulty moving on from a page after they had completed 
questions, and that they sometimes had error codes when clicking on the initial link.  These hurdles 
might have deterred individuals from participating in the survey, or in continuing a survey they 
had already started, contributing to the high dropout rate (45%).  In examining the response rate 
per question, it became clear that there was a significant drop in answers in the latter half of the 
survey.  Disease severity questions were present early in the questionnaire, and had fewer drop-
outs than other measures.  This suggests that the survey was too long to sustain the attention of 
participants and needs to be shorter in the future in order to facilitate greater completion numbers.  
There might be a correlation of individuals from higher socioeconomic statuses having a computer 
and therefore, having access to the survey.  These individuals might also have had better access to 
healthcare and social support, which could have impacted our response rates.  
 It is important to note the limitations in our comprehensive sample.  Members of existing 
IBD, online support groups were sampled, which could be perceived as sampling bias.  
Individuals in these support groups might have already had low levels of perceived social 




online support.  Individuals utilizing online social support resources might also be exhibiting 
very severe symptoms, which may make it difficult to leave their homes to seek outside support.  
Disease severity is a significant variable in our study, which can alter greatly between patients 
who have active disease versus quiescent, or dormant, disease.  According to Bonaz and 
Bernstein (2013), patients who were asymptomatic during the period of testing (whose disease 
was inactive for that period of time) had QoL scores that aligned closely with individuals from a 
non-IBD sample.  This is critical to discuss in the findings of this study, as some feedback was 
given by participants, is support of this research after they had completed the survey.  The link 
was posted on social media pages, and individuals had the ability to comment at the bottom of 
the entire post if they wanted to, with no connection to the data they had already submitted to 
Qualtrics.  A common theme in the comments was that they could have answered the survey as 
two different people—one prior to surgery or effective treatment management when their 
symptoms were very severe, or one post-surgery or effective treatment management where their 
symptoms were greatly improved and controlled.  Individuals stated that because they answered 
the survey questions based on their current state (predominantly those in the more controlled 
state with less severe symptoms), they answered questions far more positively than they would 
have been when their disease was in a severe flare.  Although we ask participants if they have 
had surgery as a result of their struggles with IBD, we do not ask about symptoms pre-operation 
(assuming their surgery had been more than 4 weeks ago, as this is the longest stretch of time our 
survey asks the participant to respond to restrospectively).   
 More asymptomatic responses could have impacted the relationships between variables 
that we investigated, including lower scores on the IBDQ, better QoL, less anxiety, less 




medication adherence piece would likely be impacted as well, as individuals having gone 
through a body-altering surgery, as well as those who have had success with their medications, 
might be more conscientious with symptom management having experienced traumatic phases of 
uncontrollable disease.  Those individuals might take more precautions and preventative 
measures to reduce the likelihood of symptom recurrence and improve overall disease prognosis, 
like adherence to their prescribed treatment plan.   
In addition to have such great variance in the health status of respondents, we depended on 
self-reported measures to assess severity of Inflammatory Bowel Disease.  Previous studies have 
recruited participants from medical facilities and have been able to ascertain more accurate 
diagnoses of disease.  This study did not verify formal diagnoses with medical practitioners, and 
depended on the subjective interpretation of individuals who reported the symptoms of their 
disease.  While perceived severity and perceived support were measures we utilized, these are, 
nonetheless, subjective.   
There is also not a disease-specific measure for seeking social support related primarily to 
IBD, it is quite general.  The literature suggests that different chronic illnesses require different 
kinds of support, as is probably true of each individual.  It will be difficult to ascertain what 
category of support people need more or would be most willing to reach out for: financial, medical, 
social, familial, spiritual, or any other facet that might help them better cope with their illness.  
There has simply not been an examination of social support within the realm of the IBD population.  
Although perceived social support was not a moderating factor in medication adherence, it 
appears highly correlated to anxiety.  Our measures of medication adherence may not have been 
comprehensive enough to fully understand how it is impacted by disease severity and perceived 




concerning the types of social support that provide the most help to this population should be 
conducted.  In addition to examining the types of social support that are most impactful, method 
of delivery in said support should also be examined.  Seeking support via an online forum is easier 
for this population to access given their physical limitations, as such, therapy interventions that 







Table 1.  
Disease Differences between UC and CD 
 
Disease Ulcerative Colitis Crohn’s Disease 
Location Colonic mucosa only (large intestine 
and colon) 
Transmural mucosa, which includes 
entire gastrointestinal tract from 
mouth to anus 
Inflammation Inflammation occurs in a continuous 
pattern in affected areas 
Inflammation may be in patches and 
intermittent 
Pain Pain is usually in the lower left side 
of the abdomen 
Pain is usually in the lower right side 
of the abdomen 
Appearance Colon wall is thinner and shows 
continuous inflammation, ulcers do 
not extend beyond inner lining  
Colon wall is thicker and may have a 
rocky appearance, ulcers are deep 
and may extend into all layers of the 
bowel wall 
Bleeding Bleeding from rectum during bowel 
movements is not common 
Bleeding from rectum during bowel 
movements is very common 
Complications Fistulas, fissures, and strictures 
common 
Not common in UC; severe anemia 
common 
Treatment 5-Aminosalicylates (5-ASAs) and 
steroids are common, recent success 
with anti-TNF-α medications 
Steroids are common, not as many 5 
ASAs are used, first to show success 
with anti-TNF-α medications 
Surgery Total colectomy (removal of large 
intestine and colon) is considered a 
‘cure’-patient can then have internal 
or external pouching system 
Bowel resections to remove 
significant diseased portions are 
possible, but colectomy is not a 
‘cure’ because it is pervasive in the 
entire gastrointestinal tract and could 









Table 2.  
Descriptive Statistics: Combined and by Diagnosis 






 Mean + SD Mean + SD F p Mean + SD 

































Duration 15.86 <.001** 
IBDQ Sum  .25 .62 
SF-36 1.25 .27 
Depression 2.48 .12 
Anxiety 1.76 .19 
Stress 1.12 .29 
Full DASS 2.19 .14 
SocSupAvg .00 .98 
Online Sup 6.67 .01* 
MARS4 .02 .88 
Note: The following table illustrates an independent samples T-test between individuals by diagnosis (ulcerative colitis or 
Crohn’s disease).  The table illustrates what is significant at p < .05*, and p < .001**.  The means and standard deviations of the 







 Multicollinearity Diagnostics  
Dependent Variable (1 – R2) Independent 
Variable 
Tolerance 
Disease Severity (1 - .498 = .502)   
 SF36Avg .913 
 Anxiety .282* 
 Stress .253* 
 Depression .299* 
 Social Support .750 
DASS Sum (1 - .497 = .503)   
 Disease Severity .942 
 Social Support .942 
Medication Adherence (1 - .003 = .997)   
 Disease Severity .957* 
 Social Support .957* 
Medication Adherence (1-.003 = .997)   
 Disease Severity .625* 
 Depression .625* 
SF36Avg (1-.018 = .982) Disease Severity .570* 
 Anxiety  .570* 
Anxiety (1 - .466 = .534)   
 Disease Severity .958 
 Social Support .958 
Stress (1 - .401 = .599)   
 Disease Severity .959 
 Social Support .959 
*Indicates tolerance statistic is less than 1 - R2 and thus multicollinearity would present a 






Table 4.  
Suppression Diagnostics  















Disease Severity       
 SF36Avg -.143 -.143 -.136 N 
 Anxiety -.164 -.321 -.171 N 
 Stress -.164 -.209 -.105 N 
 Depression -.182 -.269 -.147 N 








Table 5.  
Correlations (N = 155)       





  1 
       
2. Sex .12    1      
3. Disease Type -.12   .02    1     
4. Disease Duration .55**   .07 -.32**    1    
5. Disease Severity  -.04   -.05   .19*  -.13    1   
6. QoL .13  -.04   .04 .00 -.14    1  
7. Depression  -.12  -.15 -.10  -.02 -.61** -.05    1 
8. Anxiety -.09   .06 -.09  -.05 -.65**  .04 .76**    1       
9. Stress  -.14   .15 -.07 .05 -.61** -.11 .81** .80**    1      
10. DASS -.15   .11 -.10 .01 -.66** -.04 .93** .90** .94**    1     
11. Perceived Social Support -.09 -.08 -.04  -.01  .21* -.10 -.47** -.33** -.37** -.43**   1    
12. Online Support -.01 -.07 -.12 .01 -.27** -.07 .30**  .28** .26** .30** -.07*    1   
13. Medication Adherence .16*  .07   .03 .00   .06  .13 -.06 -.21* -.19* -.15 -.02    -.11       1  
Note. Sex was dummy coded (0 = female, 1 = male), diagnosis type was also changed into a categorical variable (0 = ulcerative colitis, 1 = Crohn’s disease), lower scores on 
the IBDQ indicate greater disease severity. 



















































*Note: Total: N = 155.  Missing data is indicated in table.
Table 6.  





Age (N = 149) 
# of 
Participants 
# of Participants 
20-30 years 24 29 
31-40 years 24 17 
41-50 years 14  11   
51-60 years 16 7 
61-70 years 3 4 
Gender (N = 155)   
Males 16 14 
Females 69 56 
Ethnicity (N = 153)   
Caucasian 80 62 
African American 0 2 
Hispanic 2 0 
Asian 1 1 
Native American 0 1 
Other 1 3 
Country of Origin (N = 153)   
United States 51 40 
Canada 10 8 
Other 23 21 
Level of Income (N = 152)   
0-20,000 28 24 
21-40,000 21 16 
41-60,000 14 10 
61-80,000 5 6 
Over $80,000 15 13 
Level of education (N = 152)   
8th Grade diploma 1 1 
High School  19 14 
Associate’s Degree 13 8 
Bachelor’s Degree 28 18 
Graduate Degree 13 17 
Other 9 11 
Classify Disease (N = 153)   
Mild 8 10 
Moderate 35 29 
Severe 41 30 
Mental Illness Diagnosis (N = 132)   
          Depression            20 23 
         Anxiety            39 28 









Moderation effect of Perceived Social Support on the Relationship between Disease Severity and 
the full Depression, Anxiety, and Stress Scale 
  CI95%    
Predictor se Lower Upper t p 
IBDQSum -0.62 -1.59 0.35 -0.10 -.18 
 PSS -0.08 -0.12 -0.04 -0.40 -.43 
IBDQ x PSS 0.10 0.03 0.16 0.23 -.23 





Moderation effect of Perceived Social Support on the Relationship between Disease Severity and 
Medication Adherence 
  CI95%    
Predictor se Lower Upper t p 
IBDQSum .00 -.19 .12 -.38 .70 
PSS .08 -.01 .01 -.45 .65 
IBDQxPSS 0.10 0.03 0.16 .04 .97 





Moderation effect of Depression on the Relationship between Disease Severity and Medication 
Adherence 
  CI95%   
Predictor se Lower Upper t p 
IBDQSum .00 -.01 .01 .27 .78 
Depression .02 -.03 .03 .07 .94 
IBDQxDep .00 -.00 .00 -.08 .93 










Moderation effect of Anxiety on the Relationship between Disease Severity and Quality of Life 
  CI95%    
Predictor se Lower Upper t p 
IBDQSum .05 -.13 .04 -1.11 .27 
Anxiety .37 -.04 1.42 1.87 .06 
IBDQxAnxiety -.00 -.01 .00 -1.89 .06 





Moderation effect of Perceived Social Support on the Relationship between Disease Severity and 
Anxiety 
  CI95%   
Predictor Se Lower Upper t P 
IBDQ .05 -.35 -.15 -5.08 <.001 
PSS 1.23 -6.19 -1.31 -3.05 <.01 
IBDQxPSS -.00 .00 .04 2.29 .02 





Moderation effect of Perceived Social Support on the Relationship between Disease Severity and 
Stress 
  CI95%   
Predictor se Lower Upper t P 
IBDQ .06 -.39 -.14 -4.29 < .001 
SS 1.56 -7.40 1.22 -2.76 .01 
IBDQxPSS .02 -.001 .05 1.92 .06 
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Letter of Informed Consent 
 
Participants will read the following prior to responding to the questionnaires at each point: 
 
Elise Bascom, B.S. will be facilitating this study. I am a graduate student in Psychology 
at CSU (supervised by Dr. Evelinn Borrayo). I suffered from ulcerative colitis for almost 10 
years before needing a J-pouch operation.  My own personal struggle with IBD, a temporary 
ileostomy, and the lack of social support and information I received during the process, inspired 
me to devote my time researching how I could help the IBD community and educate others about 
our struggles.  
It is of great importance that you answer these questions as truthfully as possible. Your 
answers are completely confidential and will, at no time, be shared with anyone other than the 
research team involved in the study.  The first screen you encounter will ask you a series of 22 
sociodemographic and disease-related questions to aid our knowledge of participant 
characteristics.  You will then be asked to complete five separate questionnaires for the purpose 
of this study in this order: the Inflammatory Bowel Disease Questionnaire (IBDQ), the Rand 36-
Item Short Form Health Survey (SF-36), the Medication Adherence Rating Scale (MARS), the 
Depression, Anxiety and Stress Scale (DASS), and the Multidimensional Scale of Perceived 
Social Support (MSPSS).  Should all questions be answered, the five questionnaires will include 




Participant Information Sheet 
 
All personal information documented on this form will remain completely confidential.  
 
The contact details you provide will be filed separately from the following questionnaire.  The 
lead researcher of the study will be the only individual who has access to this information.   
 
Thank you for your participation in this study! 
 
 Demographic Information 
 
Today’s Date: _ _/ _ _ / _ _ 
 
Date of birth: _ _/ _ _ / _ _   Age: __ __  Sex:   Female      Male 
 
Is English your first language?  Yes / No 
 
What is your country of residence? 
1. United States  
2. Canada 
3. Other (please specify) _____________________________ 
 








What is your current employment status?    Full time      Retired    Part time      Sick leave    Unemployed     Homemaker    Student      Other …………………..…….…(please specify) 
 
What is your current level of income?    Under $20,000      $50,000-$59,999    $20,000-$29,999      $60,000-$69,999    $30,000-$39,999                  $70,000-$79,999    $40,000-$49,999      Over $80,000 
 




   Associate’s Degree     Other……………….(please specify)    Bachelor’s Degree 
 
What is your marital status?    Married        Divorced    Living together       Separated    Single        Widowed    Dating/in a relationship 
 
How many children do you have?  
a) No. of daughters:  _____        
b) No. of sons:   _____ 
c) None    
 
Have you ever been diagnosed by a professional with one (or multiple) of the following 
mental health conditions?  
a) Depression 
b) Anxiety 
c) Other (please specify) _____________________________ 
 
Have you ever been formally diagnosed with an Inflammatory Bowel Disease?  Yes / No 
 
With which form of IBD have you been diagnosed: 
a) Crohn’s disease 
b) Ulcerative Colitis 
c) Diverticulitis  
 





Are you currently taking any medications?  Yes / No 
  
If yes, please give details …………………………………………………………………  
 
Have you had surgery in which one of the following was performed: bowel resection, 
temporary ileostomy/colostomy, or permanent ileostomy/colostomy as a result of your 
IBD?    Yes / No  
  If Yes, which? …………………………………………...... 
 
Have you had a previous hospital admissions for your condition?  Yes/No    
If Yes, how many? ……………………. 
 




Have any of your immediate/extended family members been formally diagnosed with IBD?   
Yes / No 
If Yes, who?....…………………. 
 
Have you been diagnosed with any other autoimmune disorder or other serious, medical 
condition in addition to IBD? Yes/No 
 If Yes, what? ...................................... 
 
Could you briefly describe your relationship with your GI doctor or the main physician 




Inflammatory Bowel Disease Questionnaire 
 
The Inflammatory Bowel Disease Questionnaire (IBDQ) 
This questionnaire is designed to find out how you have been feeling during the last 2 weeks.  
You will be asked about symptoms you have been having as a result of your inflammatory bowel 
disease, the way you have been feeling in general and how your mood has been.  Please select 
one answer for each of these questions.  If you are unsure about how to answer any question, just 
give the best answer you can.  Do not spend too much time answering, as your first thoughts are 
likely to be the most accurate.  
1. How frequent have your bowel movements been during the last 2 weeks? 
a. Bowel movements as or more frequent than they have ever been 
b. Extremely frequent 
c. Very frequent 
d. Moderate increase in frequency of bowel movements 
e. Some increase in frequency of bowel movements 
f. Slight increase in frequency of bowel movements 
g. No increase in frequency of bowel movements 
2. How often has a feeling of fatigue or of being tired and worn out been an issue for you in 
the past 2 weeks? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
3. How often during the last 2 weeks have you felt frustrated, impatient or restless? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
4. How often during the last 2 weeks have you been unable to attend school or work 
because of your bowel problems? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 





5. How much of the last 2 weeks have your bowel movements been loose? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
6. How much energy have you had during the last 2 weeks? 
a. No energy at all 
b. Very little energy 
c. A little energy 
d. Some energy 
e. A moderate amount of energy 
f. A lot of energy 
g. Full of energy 
7. How often during the last 2 weeks did you feel worried about the possibility of a surgery 
because of your bowel problem? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
8. How often during the last 2 weeks did you have to cancel or delay a social function 
because of your bowel problem? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
9. How often during the last 2 weeks have you been distracted by cramping in your 
abdomen?  
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 





g. None of the time 
10. How often during the last 2 weeks have you felt generally unwell? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
11. How often during the last 2 weeks have you been troubled by the thought of not being 
able to find a restroom (bathroom, toilet)? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
12. How much difficulty have you had, as a result of your bowel problems, doing sports or 
leisure activities you would have like to have done during the last 2 weeks? 
a. A great deal of difficulty, activities made impossible 
b. A lot of difficulty 
c. A fair bit of difficulty 
d. Some difficulty 
e. A little difficulty 
f. Hardly any difficulty 
g. No difficulty, the bowel problems did not limit sports or leisure activities 
13. How often during the last 2 weeks have you been troubled by pain in your abdomen? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
14. How often during the last 2 weeks have you had trouble getting a good night’s sleep, or 
was troubled by waking up in the night? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 





f. Hardly any of the time 
g. None of the time 
15. How often during the last 2 weeks have you felt depressed or discouraged? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
16. How often during the last 2 weeks have you had to avoid attending events where there 
was no restroom (bathroom, toilet) close at hand? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
17. Overall, in the last 2 weeks, how much of a problem have you had with passing large 
amounts of gas? 
a. A major problem 
b. A big problem 
c. A significant problem 
d. Some trouble 
e. A little trouble 
f. Hardly any trouble 
g. No trouble 
18. Overall, in the last 2 weeks, how much of a problem have you had in getting to or 
maintaining the weight you would like to be at? 
a. A major problem 
b. A big problem 
c. A significant problem 
d. Some trouble 
e. A little trouble 
f. Hardly any trouble 
g. No trouble 
19. Many patients with bowel problems often have worries or anxieties related to their 
illness.  Worries about getting cancer, never feeling better or having a relapse.  How often 
in the last 2 weeks have you felt worried or anxious? 
a. All of the time 





c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
20. How much of the time during the last 2 weeks have you been troubled by feeling of 
abdominal bloating? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
21. How much of the time during the last 2 weeks have you felt relaxed and free of tension? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
22. How much of the time during the last 2 weeks have you had problems with rectal 
bleeding with your bowel movements? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
23. How much of the time during the last 2 weeks have you felt embarrassed as a result of 
your bowel problem? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
24. How much of the time during the last 2 weeks have you been troubled by a feeling of 





a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
25. How much of the time during the last 2 weeks have you felt tearful or upset? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
26. How much of the time during the past 2 weeks have you been troubled about accidentally 
soiling your underpants? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
27. How much of the time during the past 2 weeks have you felt angry as a result of your 
bowel problems? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
28. To what extent have your bowel problems limited your sexual activity during the last 2 
weeks? 
a. No sex as a result of bowel disease 
b. Major limitation as a result of bowel disease 
c. Moderate limitation as a result of bowel disease 
d. Some limitation as a result of bowel disease 
e. A little limitation as a result of bowel disease 
f. Hardly any limitation as a result of bowel disease 





29. How much of the time during the last 2 weeks have you been troubled by nausea or 
feeling sick to your stomach? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
30. How much of the time during the last 2 weeks have you felt irritable? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
31. How often during the last 2 weeks have you felt a lack of understanding from others? 
a. All of the time 
b. Most of the time 
c. A good bit of the time 
d. Some of the time 
e. A little of the time 
f. Hardly any of the time 
g. None of the time 
32. How satisfied, pleased or happy have you felt with your personal life during the last 2 
weeks?  
a. Very dissatisfied, unhappy most of the time 
b. Generally dissatisfied, unhappy 
c. Somewhat dissatisfied, unhappy 
d. Generally satisfied, pleased 
e. Satisfied most of the time, happy 
f. Very satisfied most of the time, happy 





Rand 36-Item Health Survey Questionnaire (SF-36) 
 
Rand 36-Item Health Survey Questionnaire 
1. In general, would you say your health is: 
a. Excellent 




2. Compared to one year ago, how would you rate your health? 
a. Much better now than one year ago 
b. Somewhat better now than one year ago 
c. About the same 
d. Somewhat worse than one year ago 
e. Much worse than one year ago 
The following items are about activities you might do during a typical day. Does your 










3. Vigorous activities such as running, 








4. Moderate activities such as moving a 
table, pushing a vacuum cleaner, 


























































During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of your physical health? 
13. Cut down the amount of time 















15. Were limited in the kind of work 







16. Had difficulty performing the 
work or other activities (for 







During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems 
(such as feeling depressed or anxious)? 
17. Cut down the amount of time you 















19. Didn’t do work or other activities 








20. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups? 
(Circle One Number) 
1.  Not at all  2. Slightly  3. Moderately         4. Quite a bit   5. Extremely 
   
21.  How much bodily pain have you had in the last 4 weeks (Circle One Number) 
1. Not at all  2. Slightly  3. Moderately         4. Quite a bit   5. Extremely 
22. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? (Circle One Number) 
1. Not at all     2. Slightly          3. Moderately            4. Quite a bit             5. Extremely 
How much of the time during the past 4 weeks . . . (Circle One Number on Each Line) 
23. Did you feel full of pep? 






24. Have you been a very nervous person? 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
25. Have you felt so down in the dumps that nothing cheers you up? 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
26. Have you felt calm and peaceful? 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
27. Did you have a lot of energy 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
28. Have you felt downhearted and blue? 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
29. Did you feel worn out 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
30. Have you been a happy person? 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
31. Did you feel tired? 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
32. During the past 4 weeks how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.) 
1.  All of the time   2. Most of the time   3. A good bit of the time   4. A little of the time  5. None 
of the time 
How True of False is each of the following statements for you? 
33. I seem to get sick a little easier than most people 
1.  Definitely True    2. Mostly True    3. Don’t Know   4. Mostly False   5. Definitely False 
34. I am as healthy as anybody I know 
1.  Definitely True    2. Mostly True    3. Don’t Know   4. Mostly False   5. Definitely False 
      35. I expect my health to get worse 
1.  Definitely True    2. Mostly True    3. Don’t Know   4. Mostly False   5. Definitely False 
      36. My health is excellent 





Medication Adherence Rating Scale 
 
Medication Adherence Rating Scale 
1. Do you ever forget to take your medication?   Yes/No 
2. Are you careless at times about taking your medication? Yes/No 
3. When you feel better, do you sometimes stop taking your medication? Yes/No 
4. Sometimes if you feel worse when you take the medication, do you stop taking it? 
Yes/No 
5. I take my medication only when I am sick. Yes/No 
6. It is unnatural for my mind and body to be controlled by medication. Yes/No 
7. My thoughts are less focused on my illness when I am on medication Yes/No 
8. By staying on medication, I can prevent getting sick Yes/No  
9. My body feels weird, not at all normal on medication Yes/No 
10. Medication makes me feel tired and sluggish. Yes/No 
 
Changed Question 7 as per committee approval: My thoughts are clearer on medication. Yes/No 






Depression, Anxiety, and Stress Scale 
 
Depression, Anxiety, and Stress Scale  
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the 
statement applied to you over the past week. There are no right or wrong answers. Do not spend 
too much time on any statement. 
 
The rating scale is as follows: 
0: Did not apply to me at all 
1: Applied to me to some degree, or some of the time 
2: Applied to me to a considerable degree, or a good part of the time 
3: Applied to me very much, or most of the time 
 
1. I found myself getting upset by quite trivial things  
0 1 2 3  
2. I was aware of dryness of my mouth 
0 1 2 3  
3. I couldn't seem to experience any positive feeling at all 
0 1 2 3  
4. I experienced breathing difficulty (eg, excessively rapid breathing, breathlessness in the 
absence of physical exertion) 
0 1 2 3  
5. I just couldn't seem to get going 
0 1 2 3  
6. I tended to over-react to situations 
0 1 2 3  
7. I had a feeling of shakiness (eg, legs going to give way) 
0 1 2 3  
8. I found it difficult to relax 
0 1 2 3  
9. I found myself in situations that made me so anxious I was most relieved when they 
ended 
0 1 2 3  
10. I felt that I had nothing to look forward to 
0 1 2 3  
11. I found myself getting upset rather easily 
0 1 2 3  
12. I felt that I was using a lot of nervous energy 
0 1 2 3  
13. I felt sad and depressed 
0 1 2 3  
14. I found myself getting impatient when I was delayed in any way (eg, lifts, traffic lights, 
being kept waiting) 
0 1 2 3  





0 1 2 3  
 
16. I felt that I had lost interest in just about everything 
0 1 2 3  
17. I felt I wasn't worth much as a person 
0 1 2 3  
18. I felt that I was rather touchy 
0 1 2 3  
19. I perspired noticeably (eg, hands sweaty) in the absence of high temperatures or physical 
exertion 
0 1 2 3  
20. I felt scared without any good reason 
0 1 2 3  
21. I felt that life wasn't worthwhile 
0 1 2 3  
22. I found it hard to wind down 
0 1 2 3  
23. I had difficulty in swallowing 
0 1 2 3  
24. I couldn't seem to get any enjoyment out of the things I did 
0 1 2 3  
25. I was aware of the action of my heart in the absence of physical exertion (eg, sense of 
heart rate increase, heart missing a beat) 
0 1 2 3  
26. I felt down-hearted and blue 
0 1 2 3  
27. I found that I was very irritable 
0 1 2 3  
28. I felt I was close to panic 
0 1 2 3  
29. I found it hard to calm down after something upset me 
0 1 2 3  
30. I feared that I would be "thrown" by some trivial but unfamiliar task 
0 1 2 3  
31. I was unable to become enthusiastic about anything 
0 1 2 3  
32. I found it difficult to tolerate interruptions to what I was doing 
0 1 2 3  
33. I was in a state of nervous tension 
0 1 2 3  
34. I felt I was pretty worthless 
0 1 2 3  
35. I was intolerant of anything that kept me from getting on with what I was doing 
0 1 2 3  





0 1 2 3  
37. I could see nothing in the future to be hopeful about 
0 1 2 3  
38. I felt that life was meaningless 
0 1 2 3  
39. I found myself getting agitated 
0 1 2 3  
40. I was worried about situations in which I might panic and make a fool of myself 
0 1 2 3  
41. I experienced trembling (eg, in the hands) 
0 1 2 3  
42. I found it difficult to work up the initiative to do things 























Multidimensional Scale of Perceived Social Support 
 
Multidimensional Scale of Perceived Social Support 
Instructions: We are interested in how you feel about the following statements. Read each 
statement carefully.  Indicate how you feel about each statement. 
Circle the “1” if  you Very Strongly Disagree  
Circle the “2” if  you Strongly Disagree  
Circle the “3” if  you Mildly Disagree 
Circle the “4” if  you are Neutral  
Circle the “5” if  you Mildly Agree  
Circle the “6” if  you Strongly Agree 
Circle the “7” if  you Very Strongly Agree 
 
1. There is a special person who is around when I am in need. 
1 2 3 4 5 6 7 
2. There is a special person with whom I can share my joys and sorrows 
1 2 3 4 5 6 7 
3. My family really tries to help me. 
1 2 3 4 5 6 7 
4. I get the emotional help and support I need from my family. 
1 2 3 4 5 6 7 
5. I have a special person who is a real source of comfort to me. 
1 2 3 4 5 6 7 
6. My friends really try to help me. 
1 2 3 4 5 6 7 
7. I can count on my friends when things go wrong 
1 2 3 4 5 6 7 
8. I can talk about my problems with my family. 
1 2 3 4 5 6 7 
9. I have friends with whom I can share my joys and sorrows. 
1 2 3 4 5 6 7 
10. There is a special person i  my life who cares about my feelings. 
1 2 3 4 5 6 7 
11. My family is willing to help me make decisions. 
1 2 3 4 5 6 7 
12. I can talk about my problems with my friends. 
1 2 3 4 5 6 7 









13. I seek emotional help from online support groups. 
1 2 3 4 5 6 7 
14. Online support groups provide me with anonymity in sharing my feelings. 
1 2 3 4 5 6 7 
15. I can talk about my problems with others online because it is often a shared experience. 
1 2 3 4 5 6 7 
16. Online support groups are more accessible to me given my condition. 
1 2 3 4 5 6 7 
